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Abstract 
 
Blood–brain barrier (BBB) is a formidable barrier interface that exists between blood and brain, 
therefore, preventing therapeutic drugs or particles to enter the brain tissue. Nano-medicine is 
emerging as a prospective way for enhancing pharmaceutical product delivery to the brain with 
the development of various nano-biotechnologies. In particular, non-viral inorganic layered 
double hydroxide (LDH) nanoparticles have unique advantages over others in terms of various 
instinctive properties, such as low cytotoxicity, good biocompatibility and high drug loading 
capacity. Importantly, previous studies have demonstrated that LDHs can efficiently deliver 
siRNAs into the neuronal cells, resulting in the knockdown of the target protein. Despite the 
previous results, two major hurdles still exist before LDHs can be employed as an efficacious 
central nervous system (CNS) drug delivery system: (i) LDH aggregation upon exposure to the 
serum environment and (ii) non-specificity in the BBB penetration.  
This thesis focuses on developing novel engineered LDH delivery system with enhanced 
suspension stability, redispersion capability and brain targeting ability based on the bovine 
serum albumin (BSA) coating strategies. Angiopep2 (Ang2) and rabies virus glycoprotein 
peptide (RVG) are selected as targeting ligands as they can target to the low-density lipoprotein 
receptor-related protein (LRP) over-expressed on U87 glioma cells and nicotinic acetylcholine 
receptor (nAchR) on Neura 2a (N2a) cells, respectively. These two ligands can also target the 
endothelial cells which form the BBB. Moreover, the manganese ions are incorporated into the 
LDHs system to form magnetic nanoparticles that can act as the potential theranostic agent for 
simultaneous brain imaging and delivery.  
First of all,  BSA coated LDHs are further crosslinked by glutaraldyhyde (GTA) to improve 
the suspension stability and residpersion capability based on previous BSA coating strategies.  
Enhanced colloidal stability and excellent redispersity have been achieved compared with 
uncrosslinked BSA-LDHs and pristine LDH nanoparticles, with negligible effect on cell 
cytotoxicity and cell uptake. Thus, the newly developed GTA crosslinking strategy provides a 
solid LDH-based platform for the following in vitro and in vivo studies. 
Subsequently, LDHs-based targeting delivery system has been developed by conjugating 
ligand Ang2 or RVG with LDHs through BSA (Ang2-NPs and RVG-NPs) for brain tumour 
targeting. In vitro cell uptake shows that the Ang2-NPs and RVG-NPs have enhanced delivery 
efficiency and demonstrated specificity to relative cells. MTT assay and hemolysis study shows 
that the newly fabricated various LDH formulations have good blood compatibility and less 
 III 
 
cytotoxicity. Moreover, incorporating anticancer drug 5-FU with the LDH targeting system 
results in increased cell growth inhibition in comparison with the unmodified LDHs. Thus, this 
research provides a facile approach for ligand modification and synchronous maintenance of 
colloidal stability with narrow batch-to-batch variation. 
Then, in vivo and in vitro brain targeting ability of ligand modified LDHs has been evaluated. 
Endothelial cells (bEnd.3 cells) are the major cells that constitute BBB with both Ang2 and 
RVG receptors overexpressed. In the in vitro cellular uptake study and in the in vitro BBB 
model, the Ang2/RVG-NPs demonstrate increased cellular uptake and BBB penetration 
compared with NPs. In vivo confocal neuroimaging (ICON) results clearly show that the ligand 
modified LDH nanoparticles have longer retention time in the retina vessel. The in vivo optical 
imaging study confirms that the Ang2 ligand better target the mouse brain than RVG, which is 
consistent with the ICON observation that RVG-NPs disappear much more quickly than Ang2-
NPs.  
Moreover, we have synthesised a new manganese-based bifunctional LDHs (Mn-LDHs) for 
brain cancer theranostics. The newly designed Mn-LDHs exhibits similar biocompatibility and 
excellent gene delivery efficacy to normal LDHs. Incorporating the contrast agent Mn into the 
LDHs system endows themselve as contrast agents for MRI imaging. Compared with 
commercial Gd (DTPA)-based contrast agent (r1 ≈ 3.4 mM −1 s −1), the Mn-LDHs demonstrate 
relatively high r1 value (4.47 mM −1 s −1). In consistence, the Mn-LDHs loaded with the cell 
death siRNA (CD-siRNA) show higher cytotoxicity to cancer cells than the free CD-siRNA, 
and cause significant brain tumour cell growth inhibition. Supportively, the amount of Mn-
LDHs used for CD-siRNA delivery has been examined to be enough for MRI imaging of the 
cancer cells. Collectively, the obtained bifunctional Mn-LDHs show great potential 
applications as highly effective bimodal imaging and delivery for cancer diagnosis and 
chemotherapy simultaneously.   
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            Chapter 1 
Introduction  
 
1.1 Significance of the project 
 
At the moment there are no effective non-toxic particle carriers for diagnostic agent and new 
drug delivery to the brain cancer.1,2 Layered double hydroxide (LDH) nanoparticles (NPs) have 
great potential as a drug delivery and imaging system.3-6 However, two major hurdles remain 
before they can be used for this purpose. LDHs aggregate once upon exposure to the 
bloodstream and the blood-brain barrier (BBB) prevents the passage of most molecules and 
particles from the blood into the brain.7, 8 The goal of this project is to overcome these obstacles 
using novel nano-engineering strategies to prevent LDHs aggregation and enhance their 
passage across the BBB. In this project we will develop next-generation LDH nanoparticles 
that are able to act as Trojan horses to carry drugs into the brain and simultaneously provide 
imaging capacity for therapeutic efficiency prediction. 
Ideally, one would like to administer LDH-based drugs via the intravenous route. 
Unfortunately, LDH aggregation and rapid clearance from the bloodstream have limited this 
approach, thus improvement in the suspension stability is necessary.9, 10 This project aims to 
use a facile way to engineer LDH nanoparticles with improved colloidal stability and BBB 
penetration ability as well as imaging capability. Therefore, the significance of this project is 
the development of efficacious LDH formulations that are suitable for intravenous injection 
and are able to efficiently penetrate the BBB. Moreover, understanding the surface engineering 
of LDH NPs will provide essential insights into the design and development of many other NP-
based drug delivery systems. Any advancement in the specific aspect would produce huge 
scientific, social and economic impacts. Of further significance is the development of an 
effective delivery system for siRNA, thereby allowing RNA interference to realise its 
therapeutic potential.  
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1.2 Research objectives and scope 
The leading goal of this research is to establish a stabilised LDH nano-composite platform by 
gaining insights into LDH surface functionalisation and doping element Mn into LDHs for 
brain tumour targeting and imaging performance. This thesis does not only develop a facile 
approach to surface modifying nanoparticles with the novel hierarchy, but also provides some 
guidelines in designing multifunctional nanoparticle-based platform for various biomedical 
applications. 
The objectives of this project are specified as follows: 
1) To enhance LDH suspension stability and redispersion capability through cross-linking 
albumin coated on LDHs; 
 
2) To improve cellular uptake of LDH NPs by U87 glioma cells and neuroblastoma N2a cells 
through conjugating targeting ligand (Ang2 or RVG) via surface-coated albumin; 
 
3) To confirm the increased BBB penetration of ligand modified-LDHs in the in vitro and in 
vivo models; 
 
4) To develop dual-functional Mn-containing LDHs for simultaneous brain magnetic 
resonance imaging and siRNA delivery.  
 
1.3 Thesis outline 
This thesis is written according to the guidelines of the University of Queensland. The 
outcomes of this PhD thesis are presented in the form of journal publications. The chapters in 
this thesis are presented in the following sequence. 
Literature on recent advances in brain cancer diagnostic/treatments is comprehensively 
reviewed in Chapter 2. Nanoparticle-based systems for brain accumulation and targeting, 
especially the current strategies to engineer LDH nanoparticles as effective delivery/imaging 
system are reviewed in details. In Chapter 3, the strategies and approaches utilised in the whole 
PhD project are summarized, including material synthetic methods for layered double 
Chapter 1 Introduction 
3 
 
hydroxide nanoparticles and surface modification, and the techniques for material 
characterisations and biology experiments. 
One of the key challenges for nanoparticles to be used as the delivery and imaging system for 
in vivo application is their colloidal stability. Therefore, Chapter 4 presents our surface 
modification of LDH NPs, i.e. BSA coating and further GTA crosslinking, the enhanced 
colloidal stability regardless of dilution times and solutions (e.g., PBS) and the improved 
redispersion capability. This modification does not affect the delivery efficiency and in vitro 
cytotoxicity to either normal cells or cancer cells. The new strategy therefore provides a much 
more effective method to prevent LDH nanoparticle aggregation and improve LDH 
nanoparticle dispersion for usage in a wide variety of bio-applications in vitro and in vivo.  
Active targeting is supposed to increase the therapeutic index. Therefore, Chapter 5 describes 
the details of conjugating two brain tumour targeting ligands (Ang2 and RVG) onto LDHs and 
subsequent targeting tests. It is known that Ang2 and RVG ligands are able to target to low 
density lipoprotein (LRP) receptors and nicotinic acetylcholine receptors (nAchR) that are 
expressed on U87 and N2a cells, respectively. Ligands are conjugated to the LDHs through 
inter-matrix bovine serum albumin (BSA), rendering the LDHs simultaneously excellent 
colloidal stability and targeting ability. Such modification is reproducible with narrowly batch 
to batch variation. In vitro studies have demonstrated higher cellular uptake efficiency for 
ligand conjugated LDHs compared to unmodified LDHs. This new approach may contribute 
to rationally design of targeted nanoparticles, showing great potential as a promising platform 
for selective and effective therapeutic treatment of neural diseases.  
Chapter 6 further presents our examination of the brain targeting ability of ligand-modified 
LDHs through in vitro and in vivo models.  LDHs labelled with fluorescent markers and 
targeting ligands (Ang2 and RVG) are significantly taken up by endothelial cells and much 
more quickly penetrate through the simulated BBB constructed with the endothelial cells in 
comparison with non-targeted LDHs. The in vivo model also reveals that Ang2 modified LDHs 
demonstrated better brain accumulation ability compared to RVG modified LDHs and non-
targeted LDHs. This work implies that ligands have different affinity towards receptor-
expressed cells, and thus smart selection of ligands is able to achieve greater efficacy.  
Currently, the nanoparticle-based systems have come to a multifunctional era. Thus Chapter 7 
reports a new dual functional manganese-based layered double hydroxide nanoparticles (Mn-
LDHs) as an effective anticancer drug (Cell Death siRNA (CD-siRNA)) delivery system and 
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biological T1-weighted magnetic resonance imaging (MRI) modality for cancer theranostics. 
The newly designed system shows simultaneously highly effective bimodal imaging and gene 
delivery for brain cancer diagnosis and therapy. 
Chapter 8 finally presents our general discussion of the work in this thesis and the outlook for 
the future work, as a conclusion of this thesis. 
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              Chapter 2 
Literature Review 
 
This chapter reviews the advances in the nanoparticles-based medications for brain cancer 
therapy and imaging, beginning with an introduction of inhibitory biomolecules for the brain 
cancer treatment. Therapeutic chemotherapeutic drugs and genetic molecules as promising 
medications for brain cancer therapy will be introduced in details in this section. The existence 
of BBB as a major challenge of brain tumour treatment is subsequently interpreted. The current 
therapeutic strategies including invasive local delivery methods and systemic treatments, and 
advances in nanoparticle-based theranostic strategies for brain tumour will be then summarized. 
In specific, the engineering of layered double hydroxide (LDH)-based nanoparticles will be 
systematically described. Finally, a summary of current state-of-the-art technologies and 
challenges to fabricate bio-applicable LDHs for BBB passage are provided, and the basic 
research strategies for this thesis are outlined.  
 
2.1 Brain tumour and inhibitory biomolecules 
2.1.1 Brain tumour 
Brain serves as a control centre of the nervous system, which is responsible for speech, memory, 
intelligence and movement, and precise functions for coordination and regulation of many 
organs.1 Problems, such as loss of brain cells, lead to stroke that can affect the ability to think 
clearly while inflammation in the brain can cause vision loss, weakness and paralysis. There 
are many brain diseases happening to people with age-related neurodegenerative conditions, 
such as Alzheimer's disease, Parkinson’s disease and stroke.2 Some brain diseases like brain 
tumours may press on the adjacent nerves and interfere with normal brain functions. Some 
brain diseases are neurogenic diseases such as Huntington’s disease and muscular dystrophy, 
some other diseases like spinal cord and head injury belong to trauma. Depending on the 
specific problems, the symptoms of brain diseases vary widely. Some damages are permanent 
while sometimes, treatments such as medicines, surgery, or physical therapy can cure or at least 
weaken symptoms.3, 4 This thesis will involve in the brain tumour study. 
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Tumour can be defined as tissues that grow in an undisciplined manner other than normalised 
growth. Brain tumours can be classified as two categories, namely benign and malignant cancer, 
depending on the tumour phase. The periphery margin of benign cancer is easy to be identified, 
therefore, it is easy to be removed and there is rare recurrence. However, the malignant brain 
cancer is composed of cancerous cells which invade and infect the surrounding healthy part of 
brain. Such a spread of malignant cancer to the border of the other tissues is called metastasis. 
Classified by different original area, neuroblastoma, glioblastoma, meningioma and 
astrocytoma can be categorised into the primary brain tumour. Metastasis tumours originated 
from cancers such as breast cancer or melanoma are classified into secondary brain tumour.5 
Of all the primary brain cancer, the glioblastomas account for 40% while neuroblastoma is a 
common solid tumour derived from primitive cells of the sympathetic nervous system.6 This 
thesis will involve in the study of glioblastomas and neuroblastoma. As an essential complex 
and interconnected network, brain is able to balance regional segregation and functional 
specialisation with strong integration. However, the devastating results can happen when the 
brain tumour occur. Due to the intrinsically persistent severity and infiltrative nature, treatment 
of both primary and metastatic brain tumours remain as a formidable challenge.7  
2.1.2 Inhibitory biomolecules as potential brain tumour therapeutics  
Inhibitory biomolecules including gene-based and chemotherapeutics have been widely 
applied in the tumour treatment at the moment. Brain tumours induced by hereditary genetic 
factors with aberrant proteins expression imply a potential gene therapy by targeting and 
suppressing the mutant proteins at the gene expression level.8 Abundant research work has 
been conducted on the use of antisense oligonucleotides (ODNs), peptide nucleic acids (PNAs) 
and more recently, small interfering RNA (siRNAs) as potential therapeutics.9,10 
Complementarily, chemical substances such as 5-Fluorouracil (5-FU), Doxorubicin (Dox) and 
paclitaxel based chemotherapy are also employed for brain cancer treatment, aiming to kill the 
cancer cells, thereby prolonging patient’s life and reducing the disease symptoms.11 
2.1.2.1 Gene-based drugs  
Gene therapy now is applied as a new treatment for neurodegenerative diseases or brain cancers 
to target the specific disease area where the encoded protein will be produced or the mutant 
protein will be knocked down. The transferred gene could also correct a mutation or encode a 
protein with therapeutic function.12 Several reports have successfully used the gene to treat 
brain cancer. Asgharzadeh et al. reported that the PID1 (Phosphotyrosine Interaction Domain 
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containing 1; NYGGF4) has tumour inhibition function in glioblastomas.13 Retroviral vector 
with herpes simplex thymidine kinase (HS-tk) gene insertion is produced by murine fibroblasts. 
The vectors were intratumoral stereotaxic injected into rats planted with cerebral glioma, with 
the aid of anti-herpes drug ganciclovir at 5 days, gliomas were found to regress completely.14 
Despite the encouraging results, the degradation of the naked gene by serum nucleases has 
intensively limited its clinical application once upon exposure to the blood after administration 
injection. Responding to the insufficiency in therapeutic delivery, many research efforts have 
recently made on the exploration of new strategies to offer more effectively gene delivery to 
the central nervous system (CNS).15 In this thesis, a cell death siRNA (CD siRNA) which is 
believed to have the ability to kill cancer cells in some way was employed.  
2.1.2.2 Chemotherapeutic drugs 
Several chemotherapeutic drugs are used to treat brain cancers. Dox is one of the most widely 
used anticancer agents. Studies of free Dox find efficient inhibition of the malignant brain 
tumour growth when injected directly into the brain tumour site.16 Delivery system like 
liposomes encapsulating Dox shows enhanced accumulation in the brain tumour with increased 
life span.17, 18 Paclitaxel is another kind of hydrophobic chemotherapeutic drugs used for brain 
tumour treatment.19 The systemic treatment by paclitaxel is always not sufficient enough for 
cancer cure, therefore, a lot research is focused to encapsulate paclitaxel into microspheres for 
localised delivery to brain tumour.20 Cell cycle and cytotoxicity studies of paclitaxel to C6 
glioma cells show that the cells are inhibited in G2/M phase and increased cytotoxicity 
compared with control group is observed.21, 22 In addition, the other chemotherapeutic drugs 
used for brain tumour treatment including the camptothecin and temozolomide are not so 
popular, but also investigated.23, 24 Hydrophilic 5-FU belongs to anti-metabolic drugs, working 
through irreversible inhibition of thymidylate synthase.25, 26 An investigation by using the 
combination of 5-FU with hyperbaric oxygen for treating malignant tumours has found that the 
concomitant hyperbaric oxygen enhanced the antitumor effects of 5-FU by reducing the tumour 
volume more than one time.27 Clinical phase I trial of 5-FU formulations for glioma treatment 
by Menei with 10 patients was performed, and the overall median survival was 40 weeks, with 
2 long-term survivors (71 and 89 weeks).28 These results clearly indicate that the 
chemotherapeutic drugs are useful for brain tumour treatment in some situations.  
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2.2 Blood brain barrier: a challenge in the brain tumour treatment  
2.2.1 History  
The first hint of BBB existence was shown when a bacteriologist Paul Ehrlich using chemical 
dyes to stain biological structures by microscope. All the organs can be stained except the brain 
area after intravenous administration. At that time, it was attributed to the brain that has a low 
affinity for the dye. Then later in 1913, Edwin Goldmann performed an experiment, in which 
he injected the dye directly to the cerebrospinal fluid (CSF) rather than the vein. He found that 
the brain was stained but the rest of the tissues were not. In this case, he claimed that there was 
something acting as a barrier to separate the CSF and blood. However, due to the lack of an 
advanced technique for observing the existence of the barrier, this concept has only widely 
accepted after the employment of the scanning electron microscope to medical research.29 
2.2.2 Structure  
 
 
Figure 2.1 Barriers to CNS access. The neurovascular unit is composed of the endothelial 
lining, the basal lamina, ensheathed pericytes and astrocytic endfeet.30 
The necessary of maintaining central nervous system homeostasis prompts the BBB to develop 
into a strictly complicated interface between the blood and the CNS. The BBB is mainly formed 
by the cerebral endothelial cells along the brain and spinal cord capillaries, connected by tight 
continuous junctions and surrounded by a series of perivascular cells including smooth muscle 
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cells, pericytes, microglial cells and astrocytes (Figure 2.1).31, 32 In this way, the central nervous 
system is separated from the peripheral environment and can be protected from the fluctuations 
action of compounds transporting into or out of the periphery, thereby decreasing the 
interference to neuronal exchange to a larger extent. Protecting the neurons within the brain 
and spinal cord is the main element that facilitates BBB evolution. Not all the creatures own 
such a complicated BBB structure, apart from the advanced nervous system creatures. 
Cuttlefish has an intermediate level of BBB participating with pericytes in the development of 
barrier in big veins. Insects, molluscs and fish have the lower BBB evolution, and their barriers 
are only formed by glial cells.33-35 Ionic homeostasis maintenance is treated as the most 
significant consequence of the BBB development. Creatures with a higher level of homeostasis 
maintenance in the interstitial medium of the cerebrospinal fluid possess a much advanced 
evolutionary level.36 
2.2.3 Possible transportation ways across the BBB  
 
Figure 2.2 Therapeutic brain delivery strategies that target the physiological make-up of the 
BBB. (A) Transport mechanisms though the BBB. (B) A wide range of receptors that mediate 
transport through transcytosis.37 
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The existence of BBB selectively allows free passage of molecules such as water, O2, CO2 and 
small hydrophobic substances that are crucial to neural functions. However, vast majority of 
substances that are useful for brain tumour therapy or diagnostic are characterised to possess 
low BBB permeability.38, 39 In an attempt to functionally access the BBB, it is necessary to 
comprehensively understand the intrinsic BBB features and meanwhile combine with the 
possible transport routes in a full-scale. The transcellular route plays a much important role in 
the delivery of different substances such as peptides, antibodies and siRNA through the BBB. 
These routes consist of paracellular aqueous pathway, carrier-mediated transport, receptor-
mediated transcytosis and adsorptive-mediated transcytosis (Figure 2.2A).40 
2.2.3.1 Passive diffusion into brain 
BBB permeability through passive diffusion of compounds is associated with their lipophilic 
properties. Many lipid-soluble molecules and gaseous molecules such as O2 and CO2 can 
diffuse though the BBB and enter the brain passively, hence compounds of greater lipophilicity 
generally show higher permeability. However, these molecular and physicochemical factors 
are not always absolute elements for CNS penetration. In contrast, there are many examples of 
effective therapeutic CNS drugs that are lipophilic but not BBB-permeable.  Sometimes, the 
solutes with positive charge is considered probably to be able to interact with the negatively 
charged cell membrane, which facilitates their entry through the BBB.41 
2.2.3.2 Adsorptive-mediated trans-BBB delivery 
Adsorptive-mediated transcytosis (AMT) provides a means for brain drug delivery through 
electrostatic interactions between cationic molecules and anionic cell membrane of the brain 
capillary endothelial cells. AMT-based drug delivery to the brain can be achieved using 
cationic proteins or basic peptides such as cell-penetrating peptides (CPPs) as the ligand. Large 
therapeutic molecules such as peptides and proteins can be transported across BBB to brain 
parenchyma through AMT.42  
2.2.3.3 Transporter-mediated trans-BBB drug delivery  
A wide range of solutes and drugs such as glucose, amino acids, purine bases, nucleosides and 
choline have a much lower CNS entry rate. It is because these substances and many of their 
metabolites are able to be actively effluxed from the brain by ABC transporter (ATP-binding 
cassette) family.31 Among energy-dependent transporters, P-glycoprotein (Pgp) is one of 
typical member and displays recognition specificity towards hydrophobic substrates. The 
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major role of the ABC transporters in the BBB is to function as active efflux pumps consuming 
ATP and transport a diverse range of lipid-soluble compounds out of CNS. In other words, 
they remove potential neurotoxic endogenous or xenobiotic molecules from the brain and carry 
out a vital neuroprotective and detoxifying function.43 In this way, the brain penetration of 
drugs that are substrates for these ABC efflux transporters is significantly reduced by this 
transport activity.  
2.2.3.4 Receptor-mediated transcytosis  
A series of receptors expressing on the BBB provide possible active targeting through ligand-
receptor, antigen–antibody and other forms of molecular recognition to a specific location (Fig. 
2B).44 Receptor-mediated transcytosis could increase penetration rate and reduce potential side 
effects.45  
One example of large molecule drugs that have shown promising clinical results are the 
angiopeps, the receptor of which is low-density lipoprotein receptor (LRP) that ubiquitously 
expressed on BBB cells. Among the ligands for LRP, Angiopep-2 (Ang2) shows a higher brain 
penetration capability than other proteins of LRP-related family and most other proteins that 
target to the BBB, such as aprotinin and transferrin.46, 47 Moreover, Angiopep-2 is proven to be 
a dual-functional ligand for brain tumour-targeting, which is also overexpressed on glioma 
cells.48 Nicotinic acetylcholine receptors (nAChRs) are widely expressed in the BBB and 
neurons that located in various parts of the central nervous system. A 29 amino-acid short 
peptide derived from the rabies virus glycoprotein (RVG) is applied as another dual targeting 
ligand for brain as RVG can bind to acetylcholine receptors.49 In addition, lactoferrin, 
transferrin and insulin are also reported to have great potential in targeted drug delivery across 
the blood brain barrier.50    
2.2.4 Summary  
Treatment of brain cancers remains as a challenge due to the BBB and potential inefficient 
drug concentraiton. As a brief conclusion, the receptor-mediated transcytosis strategy for 
overcoming BBB holds great potential for highly improved drug delivery towards brain. Due 
to the dual targeting ability of Ang2 and RVG peptide towards brain cells, they were selected 
for the brain targeting work in this thesis.   
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2.3 Therapeutic strategies for brain  
Due to the infiltrative nature of primary brain tumours and the rigorous BBB features, it is 
extremely hard to diagnose and treat the brain tumour, and advanced techniques are required 
to improve the therapeutic outcomes towards this devastating disease. During the last decades, 
numerous strategies have been investigated for improved drug delivery to the dreadful brain 
tumours and overcome the BBB (Figure 2.3). There are invasive and non-invasive techniques 
that are not maturely developed for brain tumour treatment.51 In this section, the pitfall and 
potential of current methodologies will be briefly discussed. Nanoparticle-based strategy that 
are used to deliver a spectrum of chemotherapeutic, diagnostic and imaging agents for various 
applications will be intensively interpreted.52 
 
Figure 2.3 Strategies for enhanced drug delivery against brain tumour.53 
 
2.3.1 Invasive local delivery methods  
To mediate the direct drug administration to brain parenchyma, local delivery methods include 
the convection-enhanced delivery, gliadel wafers, osmotic BBB disruption and ultrasound-
induced BBB opening have been investigated. These methods have the potential benefit of 
decreasing systemic toxicities and overcoming the lack of BBB permeability.53, 54  
Convection-enhanced delivery (CED) uses the implanted infusion catheters that allows 
continuous drug delivery during surgery. A hydrostatic pressure gradient via convective flow 
through the parenchyma enables the drugs to reach all the tumour cells.55 Gliadel wafers are 
implantable polymer wafers placed at the tumour resection site. Due to the high cost, gliadel 
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wafers are rarely used. Both of these two techniques are confronted by the problems that drugs 
are washed away in the systemic circulation which is known as sink effect.56 The hyperosmolar 
agent mannitol is another option for brain malignancies treatment. By injecting mannitol 
solution in advance to the carotid artery, the inner and outer brain pressure environment maybe 
changed due to the administration of hypertonic solution which leads to alteration of BBB 
structure. After a period of 30 seconds, administering antitumor compounds to the same artery 
through the same method, the BBB passage ability of compounds are greatly increased.57 It is 
reported that the antitumor agents in brain were increased by 3 to 20 times while the penetration 
ability was increased by 2 to 6 times in the existence of mannitol. However, side effects are 
accompanied with this method, and injection with mannitol causes apoptotic in the brain 
relevant cells as a result of the tiny transformation in the central nervous system. A high 
concentration of this foreign substances may even make the patients convulsive and decrease 
their cognitive ability.57, 58 Transient physical modulation of the BBB also attracts much 
attention. One popular technique is ultrasound which could increase paracellular distance and 
increase passive diffusion of hydrophobic agents by reducing the efflux transporters capacity.59, 
60 Some common issues arise from BBB transient disruption still severely limits its widely 
usage, including artificial complexity, immature technology, potential of pernicious tumours 
or products invasion from BBB to peripheral tissues. Apart from these challenging problems, 
evaluation of the BBB transit efficiency is another issue that needs consideration.61   
All above mentioned methods offer some improvements of the treatment outcomes. Obviously, 
in the other side, all these invasive treatments are associated with complications that we cannot 
ignore. Although combining different strategies may use their strength, these techniques need 
to be intensively improved and promoted to reach an acceptable drug accumulation 
concentration for the remedy of brain diseases. Besides, due to lack of protective shield, these 
techniques also tend to easily lose drug activity. In addition, the healthcare costs of treatments 
are likely to be enormous in the long recovery period.51   
2.3.2 Systemic treatment strategies  
In systemic therapy, drugs are delivered either orally or intravenously as well as via the 
olfactory route, while adequate delivery to the brain relies on BBB penetration. This type of 
therapy is less invasive, however, the drug concentration at the brain disease site often falls to 
sub-therapeutic levels due to the restriction of BBB, plaguing by the fact of offsite toxicity. In 
general, for enhanced brain accumulation, the drugs should either be able to overcome the 
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efflux transporters or take advantages of innate influx transporter systems expressed at the BBB. 
For inhibiting the efflux transporters, it is achievable through chemical modification to reduce 
their efflux liability. A typical studies of efflux transporters inhibition were performed through 
engineering the efflux substrate GNE-317 with less substrate activity, and finally GNE-317 
was found to be uniformly distributed throughout tumour and normal brain regions.62 Receptor-
mediated transcytosis and transporter-mediated trans-BBB drug delivery are two methods that 
mediate active transport.These two methods are able to take advantages of innate influx 
transporter systems expressed at the BBB for systemic brain cancer treatments.63  
2.3.3 Nanotechnology-based strategy  
The research about nanoparticle is currently a field of great interest for applications in 
biomedical, optical materials and electronic devices. Nano-carriers are delivery systems that 
range from 1 to 100 nm (not strictly to 500 nm) and can be fabricated from all sorts of 
substances, including lipids, inorganic salts, polymers and carbon nanotubes (Figure 2.4).64,65, 
66 Among these nano-carriers, layered double hydroxide nanoparticles are the focus of this 
thesis and used throughout the research.  
Traditionally, enhanced permeability and retention (EPR) effect with vascular leakage is 
always expected to benefit for drug penetration into tumour area, however, EPR effect is not 
applicable for brain metastases as vascular defect is not exist in such an area.67 Achieving an 
adequate “targeted bioavailability” to the brain is essential in the treatment of brain tumours. 
A promising way to deliver drugs to the targets within the CNS is through active targeting 
nanoparticles-based system.68, 69 The goal of the present review is to highlight the recent 
findings concerning this strategy. The use of nanoparticles for imaging is also within the scope 
of the review. Moreover, nanoparticle-based brain tumour treatment could be combined with 
other BBB circumvention strategies to achieve the best therapeutic outcome.  
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Figure 2.4 Schematic structure of different nanocarriers (liposomes, polymeric nanoparticles 
including nanospheres and nanocapsules, dendrimers, and micelles) for drug delivery to the 
brain tumour.70 
 
2.3.3.1 Polymeric materials and micelles  
A polymer is large molecular mass material constituted by multiple repeated monomers and is 
made via polymerization of these monomers. Large molecule or macromolecule containing a 
wide variety of properties can be plastics such as polystyrene or derives from natural 
biopolymers such as nucleic acid or proteins that possess biological structure and function.64 
The far-ranging original materials used for polymer synthesis render these polymers many 
specific physical properties such as tenacity, viscoelasticity, semicrystallinity and biological 
functions.71 Many researches have been done to examine the potential of polymers as 
candidates in biological area, especially polyesters, including poly (lactic acid) (PLA), poly 
(glycolic acid) (PGA) and their copolymer poly (lactic-co-glycolic acid) (PLGA).72  
A micelle is composed of amphiphilic surfactant molecules or large amphiphilic block 
copolymers that are self-assembled in water into a structure of spherical vesicle with a 
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hydrophobic core and a hydrophilic exterior. Hydrophobic core in the centre of micelle allows 
the micelle to carry and protect hydrophobic drugs until they are released by some drug delivery 
mechanism while the hydrophilic surface shields the micelles from the instant recognition by 
the immune system and subsequent clearance. Traditional micelles are formed by the 
hydrocarbon portion of long fatty acids, with a polar or hydrophilic or charged head group and 
a hydrophobic tail. The size of micelles is often less than 100 nm and determined by the 
component size and geometrical features. Polymers have variable hydrophilic and hydrophobic 
features and can form micelles in water. 
The most famous copolymer is PEO (poly (ethylene oxide))–PPO (poly (propylene oxide))–
PEO with the trade names of Pluronic® and Poloxamer™. Drug delivery by micelles is 
ubiquitous and has been undergoing a long history. Block copolymer micelles conjugated with 
cell-penetrating peptide promote brain targeting delivery and thus have attracted a lot 
attention.73, 74 Angiopep-2 conjugated PEG-PLA micelles were prepared by film hydration 
method. Near-infrared (NIR) fluorescence dye, DiR was loaded into micelles to evaluate the 
brain-targeting ability of micelles by fluorescence imaging in vivo and ex vivo. Compared with 
the micelles without ligand modification, significant NIR fluorescent signal was detected in 
the brain after angiopep-anchored micelle administration. Further the whole brain and brain 
slice imaging confirmed the observations. The angiopep-PEG-PLA micelles show high brain 
accumulation for up to 24 h after intravenous administration in mice. These results indicate 
that angiopep-modified PEG-PLA micelle is a promising brain-targeting nanocarrier for 
lipophilic drugs.75  
2.3.3.2 Liposomes  
Liposomes are applied in drug or gene delivery for a long period, which is comprised by 
amphiphilic molecules with polar and nonpolar components. In the 1960s, liposome platforms 
were first well-established for managing the therapeutic and imaging agents. Only until 1973, 
the potential of liposomes as nano-scale delivery vehicle has been investigated by 
Gregorialdis.76 Since then, an explosion research on the nano-scale liposomes has been 
conducted due to their comparable simple preparation, non-immunogenic, high biocompatible 
and relatively low cost. All these features have confirmed the indisputable status of liposomes 
as a drug delivery vehicle. Generally, liposome is formed by phospholipids that generate 
unilamellar or multilamellar lipid bilayer structures under various technological conditions, 
surrounding by an internal aqueous core. Practically, liposomes components are varied with 
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amphoteric ionic, anionic and cationic lipid, therefore, the surface charge can be adjusted 
through balancing a different amount of the lipid. In the drug delivery field, the self-assembly 
liposomes are attractive because their amphiphilic feature give them superiority to encapsulate 
hydrophilic agents in the aqueous core or the hydrophobic molecules in the lipid bilayer. 
Therefore, the therapeutic drugs can be protected to keep their bioavailability. Given the 
assemblable structure and the phospholipids composition, liposomes have become an 
incontrovertible choice at one time.77  
However, there are many controversies as liposomes are unstable and easily to be captured by 
the reticuloendothelial system (RES) when the surface is coated by opsonisation proteins after 
intravenous administration into the bloodstream. Moreover, liposomes may be dissolved due 
to electrostatic, hydrophobic and other forces, and thus the system stability needs to be 
improved and many methods have been applied to address these problems. Some work has 
demonstrated that conjugated lipids with PEG tethers can increase liposome stability, allowing 
the liposomes to circulate for many days by reducing opsonin adsorption and avoiding rapid 
clearance by RES. Besides an increase in the duration of liposome circulation by modifying 
their surface with PEG, many ligands can be conjugated modified to the surface of liposomes 
in order to direct their binding to a specific receptor and alter the system random distribution 
in the organism. Evidence suggest that liposomes conjugated with ligands (transferrin, 
lactoferrin, low-density lipoprotein) show promise for drug delivery across BBB.78  
2.3.3.3 Dendrimers  
Dendrimers are a class of well-defined branched molecules with high degree of dispensability 
that surround an inner core. Typically, dendrimers can be synthesised by polyamidoamine 
(PAMAM) in an algorithmic step-by-step pattern, the more repeating units of branch layers, 
and the higher generation of the dendrimer. With functional groups on the surface, the 
dendrimers can be engineered with various targeting ligands for diverse applications. 
Negatively charged cargos (plasmid DNA, antisense oligonucleotide, and siRNA) can be 
absorbed to the high-density positively charged surface or encapsulated into the interior of the 
dendrimer. To form stable nano-composites, the dendrimer formulation should be cautiously 
modulated to achieve sufficient electrostatic repulsion.  
Moreover, the immunogenicity and toxicity are determined by the surface charge. For example, 
compared with anionic PAMAM dendrimers, cationic PAMAM dendrimers are generally more 
cytotoxic.79, 80 Targeting PAMAMs are prepared by conjugating angiopep through bifunctional 
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PEG, and then complexed with DNA to from PAMAM–PEG–Angiopep/DNA nanoparticles. 
The angiopep-modified NPs were observed to be internalized by BCECs through a clathrin- 
and caveolae-mediated energy-depending endocytosis.The cellular uptake of the angiopep-
modified NPs was also inhibited by angiopep-2, indicating that LRP-mediated endocytosis may 
be the main mechanism of cellular internalisation of angiopep-modified NPs. The in vitro BBB 
model and in vivo investigation have both demonstrated that angiopep-modified NPs show 
higher efficiency in crossing BBB and accumulated more in brain than unmodified 
counterparts.81   
2.3.3.4 Nanoparticles as MRI contrast agents  
Magnetic nanoparticles can be stimulated by magnetic field and used as contrast agents for 
magnetic resonance imaging (MRI). The current state of brain tumour imaging contributes 
greatly to improving diagnosis, tumour grading and prognosis prediction, surgery planning and 
navigation, and treatment response assessment.82, 83 MRI imaging technique together with 
computed tomography (CT) imaging and positron emission tomography (PET) imaging play a 
pivotal role for brain tumours management. CT imaging is especially useful for acute 
calcifications, haemorrhage and osseous features, providing important complementary 
information. The usage of PET imaging is limited when there are contraindications such as 
heart pacemaker existence.84  
Due to inherent depth of imaging, relatively high resolution and good contrast between healthy 
and abnormal tissues, the imaging of brain tumour has been mostly relying on the MRI. MRI 
images result from the interaction of contrast agents with surrounding tissue water protons in 
the presence of an external magnetic field.85 There are two different contrast agents for 
enhanced imaging modalities, the positive contrast agents by shortening the longitudinal 
relaxation time (T1) or the negative contrast agents by shortening the traverse relaxation time 
(T2) of the surrounding water protons. Paramagnetic gadolinium chelates and manganese 
complexes belongs to the T1-weighted contrast agents and create bright T1-weighted signal 
intensity. On the other hand, superparamagnetic iron oxide nanoparticles (SPIONPs) belongs 
to the T2-weighted contrast agents and generate the dark T2-weighted MR signal. 
Nanoparticles are comprised by different matrices, by incorporating different contrast agents 
into the nanoparticle system, and can be endowed with MRI imaging capability.86, 87    
Nanotechnology-based systems for versatile payload delivery with favourable 
pharmacokinetics and synchronously imaging represent a new era of “theranostic” for 
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enhanced therapeutic index. Multi-functionality can be engineered into magnetic nanoparticle 
systems for tumour specific detection, treatment, and follow-up monitoring.88, 89 Xu et al. 
reported an Gd(DTPA)2- intercalated layered double hydroxide (LDH) nanomaterials. The new 
LDH complexes exhibited 4 times enhancement of longitudinal proton relaxvity compared with 
free Gd(DTPA)2- in solution.90 Hadjipanayis et al. synthesised an iron oxide nanoparticles 
(IONP) that are conjugated with an antibody for targeting to epidermal growth factor receptor 
(EGFR) expressed on the human glioblastoma multiform cells. The IONP systems are used for 
target brain tumour therapeutic and MRI contrast enhancement imaging. These functionalised 
nanoparticles are preferentially uptake by the glioma cells, activating cell apoptosis and 
inducing strong T2-weighted contrast MRI imaging. In vivo studies demonstrate increased 
survival rate of tumour implanted animals with injection of antibody conjugated IONPs, and 
these particles show selective MRI contrast enhanced images of tumour cells and target therapy 
of tumour cells.91 In another study, the polyacrylamide (PAA) nanoparticles with a core for 
encapsulating superparamagnetic iron oxide crystals and photosensitisers (Photofrin®) were 
prepared with a vascular-targeting peptides conjugation. In vivo MRI of brain tumour in a rat 
9L glioma model showed significantly higher and longer MRI enhancement of tumour in 
comparison with normal brain tissues.  The therapy by PDT is also significantly improved with 
high animal survival rate and cellular water diffusion rate by the targeted PAA 
nanoparticles.85,88 
The multifunctional clinical nature of nanotechnology provides great potential for targeting, 
therapy and imaging of malignant brain tumours.89, 92 Magnetic nanoparticles have great 
potential to be used in combination with conventional therapeutic strategies for better brain 
tumour treatment.93  
2.3.3.5 Summary  
Apart from the magnetic nanoparticles which can response to external magnetic stimuli and 
organic compounds mentioned above, inorganic nanoparticles including gold-, carbon- and 
clay-based nanoparticles are widely used for therapeutic and diagnostic purpose.94, 95 Among 
them, layered double hydroxide nanoparticles (LDHs), as one kind of clay nanoparticles which 
benefit from high drug loading capacity, good biosafety and immune system evasion have 
attracted much attention.96-98 In addition, incorporating LDHs with above mentioned ligands 
has great potential for further enhanced brain targeting.  
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2.4 Layered double hydroxide nanoparticles (LDHs)  
Since discovered in 1842 by Swedish scientists, great research interests have been attracted on 
the syntheses and applications of LDHs.99 As one type of nano-clays, LDHs show great 
promise in the theranostic, energy storage and environmental treatment area.100-102 Particularly, 
the physiochemical features and bioapplications of LDHs have been extensively investigated 
in the past few decades.103, 104 This section summarises the recent advances in the LDH-based 
nanomedicine, mainly focusing on the structure, therapeutic agent delivery, imaging and 
LDHs-based hybrids. 
2.4.1 LDH structure  
LDHs, also known as anionic clays or hydrotalcite-like materials, are a class of two 
dimensional synthetic lamellar compounds that are made up of positively charged layers with 
an interlayer region containing balanced anions and water molecules (Figure 2.5).105, 106 The 
structure is brucite-like (Mg(OH)2), where the hydroxyl anions are hexagonally close packed 
with the divalent magnesium cation filling the octahedral centres. Consequently, each 
magnesium cation is surrounded by six hydroxyl groups to form an octahedron. These octahera 
share the edges to form a infinite 2-D layer. The layers are held together by weak hydrogen 
bonds and stacked on top of each other. Part of the cations can be isomorphically replaced by 
trivalent cations with the similar size, giving positively charged layers.107, 108 The different 
stack ways of brucite-like layers result in different LDH structure, where rhombohedral and 
hexagonal are the most typical ones.107  
The LDHs can be presented by the general formula [MII1-xMIIIx-(OH)2]x+(An-)x/n·yH2O, where 
the MII and MIII represent divalent and trivalent cations.109 The preferred M2+/M3+ molar ratio 
in the natural occurring LDHs and most of the synthetic ones usually ranges between 2 and 
4.110 Generally, the isomorphical substitution with anyl divalent or trivalent cations is possible, 
giving LDHs various functions for practical applications.111, 112 
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Figure 2.5 Schematic representation of LDH structure.  
 
The most commonly used cations in the layers are Mg2+, Zn2+, Ca2+, Co2+, Ni2+, Cu2+ or Mn2+, 
and Al3+, Cr3+, Co3+, Fe3+ or Mn3+. Other LDHs containing monovalent such as Li+ and 
tetravalent metal cations such as Zr4+ have been also synthetised.113-115 The basic principle for 
substitution of divalent or trivalent cations without distortion of the LDHs structure is that the 
elements have similar radii. The radius of cations that can form LDHs can be found in Table 
1.116 The LDH stability relative to the metal cations is in the order of Zn < Ni ≈ Co < Mn < Mg 
for MII and Fe < Al for MIII.117  
Compared to cations, there are no strict selection criterion to the interlayer anions. Many 
different anionic species have been successfully intercalated. The already known interlayer 
anions include: inorganic anions (carbonate, nitrate, chloride, halides, etc.),118 organic anions 
(acrylate, lactate, terephthalate, etc.),119, 120 polymeric anions (polyoxometalates, poly(vinyl 
sulfonates, etc.)121 and biomolecules compounds (ATP, DNA, GMP, amino acid, etc.).122-124 
Anions exchange occurs with the preference following order: NO3 - < Br - < Cl - < OH- < SO42- 
< CrO42- < HAsO42- < HPO42- < CO32-. The only constraint of the anions to be intercalated is 
that the charge of anions should be properly balanced with positive charges in the sheets. 
Otherwise, the desired LDHs cannot be form by large anions with relatively low charge.125 
Notably, due to high affinity of CO32-, CO2 tends to contaminate LDHs when the other anions 
are used for the preparation. However, the nitrogen bubble can be of help to reduce CO2 
contamination. 
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Table 2.1 Ionic radii of some cations. LDHs consisting of Al3+ and Mg2+ or Mn2+ were 
primarily studied in this thesis.116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2 LDH morphology  
The most typical morphology of LDH is hexagonal sheets-like (Figure 2.6A) with 50-150 nm 
laterally width and 10-20 nm thickness. A particular rod-like LDH nanoparticles (Figure 2.6B) 
with 30-60 nm width and 100-200 nm length were reported by Xu’s group. The new rod-like 
LDH nanoparticles were identical to the hexagonal-like LDHs regarding the chemical 
composition while distinct in the synthesis conditions.126 Similarly, there is a kind of 
M2+          Radius (nm)               M3+           Radius (nm)                
Fe              0.061                        Al                  0.054 
Co              0.065                       Co                  0.055 
Ni               0.069                       Fe                  0.055 
Mg             0.072                       Mn                 0.058 
Cu              0.073                       Ga                  0.062 
Zn              0.074                       Rh                  0.067 
Mn             0.083                       Ru                  0.068 
Pd              0.086                       Cr                   0.069 
Ti               0.086                       V                    0.074 
Cd              0.095                       In                   0.080 
Ca              0.100                       Y                    0.090 
                                                  La                   0.103 
V4+                  0.058                       Li+                            0.076 
Ti4+                 0.061                       Na+                          0.102 
Sn4+                0.069                        
Zr4+          0.072 
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delaminated LDH nanoparticles that are synthesised by directly exfoliating the well-
crystallised LDHs in the nitrate form into single sheets. The newly delaminated nanosheets 
have a lateral size of several micrometres and thickness of 0.8 nm. The delamination scheme 
is shown in the Figure 2.6C.127, 128 There is not too much morphology variation of LDH 
nanomaterials. The other already known morphology change of LDHs is relevant to the hybrid 
LDHs with the other materials. A hollow LDH nanoshell was fabricated using the exfoliated 
LDH nanosheets as a shell building block and polystyrene beads as a sacrificial template 
(Figure 2.6D).129 By in situ growth, the flowerlike morphology Fe3O4@SiO2@NiAl-LDH 
microspheres with three components were synthesised, in which the LDH nanoplatelets form 
the shell on the SiO2-coated Fe3O4 magnetite core.130 
 
Figure 2.6 TEM images of (A) LDHFITC-HEX (same as LDHHEX-Cl) and (B) LDHFITC-
ROD. Reproduced from Ref 126; (C) Delamination scheme of LDHs into LDH nanosheets.127 
(D) TEM images of LDH hollow shells after treatment in air of 95% humidity.129 (E) SEM 
images Fe3O4@SiO2@NiAl-LDH microspheres.130 
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2.4.3 Pharmaceutical applications of LDHs  
Owing to the unique features such as anion exchange properties and high positive surface area, 
the pharmaceutical applications of LDHs have attracted wide interests. A lot of therapeutic 
agents and biochemical compounds such as protiens/peptides, chemotherapeutic drugs, 
vitamins and DNAs have been incorporated with LDHs through anion exchange or electrostatic 
interaction and evaluated for biomedical applications.131 Normally, LDHs have a positive zeta 
potential of 30-40 mV, which makes the LDHs suitable for adhering onto the negatively 
charged cell membrane and facilitating the subsequent cell uptake.132, 133 Moreover, LDHs own 
peculiar characteristics, such as good biocompatibility and pH-dependent dissolution, which 
aid to design smart drug delivery systems.134 The following section will interpret these 
advantages of LDHs and summarize the progresses of LDHs as delivery systems.  
2.4.3.1 Sustained/controlled release  
Controlled release refers to the delivery compounds in response to time or stimuli including 
pH, enzyme, light, magnetic field, temperature, ultrasound, osmosis, etc.135, 136 In the 
pharmaceuticals area, controlled drug release does not only intend to prolong the drug release, 
but also attempts to maintain drug level within the therapeutic window to mitigate side effects 
accompanying with potentially hazardous drug accumulation following administration.137 138 
As interpreted in the LDH structure part, the stacked layers are balanced by interlayer anions 
and the interlayer anions are exchangeable, therefore, under certain conditions of temperature, 
pH (4-7), or anion concentration, the precursor drug-LDHs could release the drug, undergoing 
the following reaction:139  
    [Mg2Al(OH)6] (drug)·2H2O + 3H+ → 2Mg2+ + Al(OH)3 + drug- + 3H2O 
The dissolution of LDHs together with the anion exchange (also known as diffusion) results in 
the release of intercalated drug. The physiological conditions can be adjusted to control the 
drug release profile by altering the temperature, pH or anions.140, 141 
Senapati et al.  synthesised a series of MgAl-LDHs with various charge density anions for 
hydrophobic anticancer drug (raloxifene hydrochloride (RH)) delivery. As reported, 80% RH 
was released from LDH-phosphate-RH within 1 h and totally released at around 7 h. On the 
other hand, the LDH-nitrate-RH showed a relative slow release rate with 60% drug released at 
6 h, then followed by a sustained release and reached total release at 42 h. The differential drug 
release rate is interpreted by interactions of drug molecules and anions with LDH constituents. 
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The charge density of nitrate and phosphate leads to different electrostatic interactions with 
LDH positive layers, therefore, leaving rest of layers interact with drug in different strength.142  
Two kinds of anti-inflammatory compounds (ibuprofen and fenbufen) were intercalated into 
the LDH interlayers via ion-exchange and co-precipitation, respectively. The release profile 
shows that 60 % of ibuprofen was released from LDH-ibuprofen at the initial 20 mins and 
sustained released to 100 % after 100 mins by ion exchange in the PBS buffer (pH=7.5). 
Fenbufen drug release was studied in a simulated intestinal fluid (buffer pH 7.8), rapid fenbufen 
release was observed during the first 15 mins and then increased linearly to 59 % after 120 
mins.143, 144 Various pH influences on the drug release are also investigated. For example, rapid 
release pattern of α-naphthaleneacetate (NAA) from LDHs was observed at both pH 14 and pH 
1 where the LDH structure was completely collapsed at pH 1.145 O'Hare et al. investigated the 
release behaviour of a series drugs including diclofenac, gemfibrozil, 4-biphenylacetic acid, 2-
propylpentanoic acid, naproxen, ibuprofen and tolfenamic acid at pH 4 or 7. Except for the 
gemfibrozil which has an identical release profile at pH 4 and 7, the other drugs all showed 
faster release at pH 4 than pH 7.146 Plenty of anticancer drugs such as 5-fluorouracil and 
methotrexate (MTX) release from LDH carrier research are shown to be fast initially and 
followed with sustained release.147, 148 
2.4.3.2 Drug delivery  
Chemotherapeutic anticancer drugs intercalated into the LDH interlayers through anion 
exchange/coprecipatation have been investigated intensively in the past two decades. Choy et 
al. reported that anticancer drug, MTX was successfully hybridised with LDHs by ion-
exchange reaction without changing significant structural and functional properties in the 
hybrids. Cellular uptake test by Saos-2 cells shows that LDHs facilitated delivery efficiency of 
MTX–LDH hybrids than MTX alone where the proliferation of Saos-2 cells was more strongly 
suppressed.149 Another study by Choy et al. successfully intercalated MTX into LDHs through 
conventional co-precipitation method. Anticancer efficacy of MTX-LDH nanohybrids was 
tested with the bone cancer cell culture lines (Saos-2 and MG-63), which showed same 
effective cell suppression at the MTX concentration 5000 times lower, showing the excellent 
delivery efficiency of MTX via LDHs delivery vector.150 A comparative cell proliferation 
suppression test between MTX and MTX-LDH nanohybrid on MTX sensitive and resistant 
cells found that the MTX-LDH nanohybrid could also bypass the MTX resistance and 
eventually effectively inhibited wild-type HOS cells and MTX-resistant HOS 
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cells proliferation compared to free MTX. They presented that the results were associated with 
uptake mechanism as the MTX-LDH nanohybrid is taken up by clathrin-mediated endocytosis. 
In this process, the nanohybrid is surrounded by clathrin-coated pit after internalisation, which 
is completely different from the cellular uptake mechanism for MTX only.151  
An interesting comparative study has evaluated the anticancer potential of chemotherapy 
agents (MTX, 5-FU, Dox) and drug-LDH compounds (MTX-LDH, 5-FU-LDH). The 
anticancer effect is in the order of MTX-LDH ˃ MTX ˃ Dox ˃ 5-FU-LDH ˃ 5-FU in all cell 
lines (Hep1, A549 and HOS).152 Other drugs such as Floxuridine, Doxifluridine (DFUR) and 
Camptothecin (CPT) are also studied and loaded into LDHs by anion exchange or precipitation 
by controlling the pH or temperature.153  
2.4.3.3 Gene delivery 
Remarkable researches have been done in the gene delivery using LDHs. Ladewig et al. 
reported that anti-MAPK1 (ERK2) siRNA was delivered to HEK293T cells by LDHs and 
resulted in a substantial knockdown of ERK2 expression by 80–90% 8 h after incubation, 
which was even quicker than the Lipofectamine.154 Specially, Wong et al. reported that cortical 
neurons are more rapidly internalising nucleic acid-LDH complexes than NIH3T3 fibroblasts. 
Thus the siRNA delivered by LDHs resulted in effective 49% knockdown of axon guidance 
receptor, DCC through clathrin-mediated endocytosis pathway.155 Moreover, the successful 
knockdown of DCC protein indicate that the siRNA is efficiently released from LDH 
nanoparticles prior to reaching the lysosome with a degradable environment.  
The gene release mechanism has been interpreted in Xu’s report. When foreign LDHs are 
internalised by the cells and transferred to the endosomal vesicles, the protons are pumped into 
the endosome, thereby facilitating the dissolution of LDHs, resulting in the release of Mg2+, 
Al3+ and Cl− ions. With the increasing concentration of ions, the water molecules enter the 
endosome and cause osmotic swelling and endosome bursting, thereby releasing the inside 
compounds into the cell cytoplasm (Figure 2.7). Most importantly, the siRNA is protected from 
the acidic environment within the endosome due to LDH's buffer capacity.126  
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Figure 2.7 Schematic illustration of LDH particle endocytosis and endosomal escape. 
Reproduced from Ref 126.  
Various factors determining gene function expression efficiency are studied. Wong et al. 
claimed that the nucleotide sequence affects their interaction with LDHs and governs the 
siRNA delivery efficiency.156 Some studies suggest that the particle size determines the siRNA 
delivery efficiency. Chen et al. reported that LDHs with a smaller particle size (45 nm) are 
more efficient in delivering siRNA in HEK 293 T cells than the particles with large size (114 
nm).157 The pEGFP-N1 plasmid DNA are also successfully transfected NSC 34 cells with high 
transfection efficiency as reported by Li et al.158 To enhance the cancer cell growth inhibition, 
a novelty system by simultaneously delivering anticancer drug 5-FU and Allstars Cell Death 
siRNA (CD-siRNA) via LDHs for effective cancer treatment are also established. The 
coordinate effect of CD-siRNA and 5-FU with the same LDH particles significantly enhances 
cytotoxicity to three cancer cell lines (MCF-7, U2OS and HCT-116) in comparison with either 
CD-siRNA-LDH or 5-FU-LDH.159  
2.4.3.4 Protein delivery  
The large positively charged surface enables LDH to carry zwitterionic biomolecules via 
electrostatic interactions. Xu et al. used LDHs to load an amount of as high as 1.1 mg Intimin 
 (IB) per mg LDHs (Figure 2.8) as adjuvant to induce strong immune responses against 
bacterial infections. IB is an outer-surface membrane protein of two dominant zoonotic enteric 
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pathogens: Escherichia coli and enteropathogenic E. coli, playing an essential role in the initial 
stage of infection. In this report, LDH-IB induces remarkable higher antibody and cell-
mediated immune responses, compared with that induced by the potent adjuvant, QuilA. 
Particularly, the long term strong immune responses last for at least four months in the mouse 
model with no obvious histopathology of the major organs.160   
Another report by Xu et al. presented that co-delivery of the toll-like receptor (TLR) ligand 
CpG and a model antigen, ovalbumin (OVA) by LDHs could modulate immune responses 
towards the preferred polarity for anticancer immunity. In this study, 0.125 mg OVA and 0.01 
mg CpG were immobilized on the surface of one mg LDHs. The complex LDH-CpG-OVA 
does not only promot the secretion of IgG1 antibody but also stimulates much higher amount 
of IgG2a at day 21 and 35 after subcutaneous immunisation. In particular, the IgG2a/IgG1 ratio 
is six times higher than that induced by Alum-CpG-OVA. This observation indicates that the 
LDH is a more flexible vaccine adjuvant, capable of inducing both Th2 and Th1 immune 
responses. As Th1 response is suitable for  anti-tumour treatment,  the mice immunised with 
LDH-CpG-OVA first showed retarded tumour growth after challenge with OVA-expressing 
B16/F10 tumour cells.161 Collectively, these data demonstrate the suitability of LDHs as useful 
adjuvants in new-generation vaccine formulations to control various infectious diseases and 
cancers. 
 
Figure 2.8 Adsorption of Intimin β (IB) to clay nanomaterials. Schematic diagrams showing 
possible interactions of LDH nanoparticles with IB through electrostatic interactions between 
-COO− groups along the IB chain and the positive charges on the LDH surface.160 
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2.4.3.5 Good biocompatibility  
Biocompatibility is an important evaluation parameter when applying a material for clinical 
usage. To be a safer material for bioapplication, the material should perform its intended 
function with desired efficiency in the host while without eliciting any unexpected local or 
systemic effect.162 The in vitro biocompatibility test of LDHs regarding cell viability test, 
hemolysis assay, thrombosis assay, lactate dehydrogenase leakage assay, inflammatory 
mediators analysis, lipid peroxidation and reactive oxygen species generation have been 
intensively investigated.163 
Choy et al. performed the toxicity test of LDHs in carcinoma A549 cells, normal L-132 cells, 
cervical adenocarcinoma cells (HeLa) and osteosarcoma cells (HOS). LDHs showed little 
cytotoxicity upon the cells proliferation and viability at the concentration below 250 μg/ml 
within 48 h. Compared with the toxicity caused by the other inorganic nanoparticles, silica 
triggered no considerable cell death but with an inflammation response, iron oxide caused cell 
death due to the cell membrane damage, and single walled carbon nanotube led to cell apoptosis 
by inducing oxidative stress. However, LDHs exhibited less cytotoxic effects on normal L-132 
cells in terms of side effects accompanying with the nanoparticles at the concentration of less 
than 250 μg/ml.164 Moreover, in comparison with polymer nanocarriers, Xu et al. reported that 
MgAl-LDH was approximately 10 times less cytotoxic than polyethyleneimine.109 
Meanwhile, the in vivo toxicity tests of LDH materials have been also performed in various 
ways. The in vivo intramuscular implantation test is a much adequate scrutinisation as it allows 
the evaluation of full biological defence by the host immune system in comparison with the in 
vitro test performed under controlled conditions. Antigenicity and tissue integration capacity 
have been investigated histologically by implanting LDH formed tablets in rat abdominal wall 
after 7 and 28 days. No inflammatory response and fibrous capsule neighbouring the LDHs 
was triggered. Moreover, the LDHs show good tissue and appropriate extracellular matrix 
remodelling as well as the deposition of collagen.163 To improve the bioavailability of LDHs 
in the colon, the oral delivery of LDHs has also been investigated by coating the pH-sensitive 
Eudragit copolymer on the surface of LDHs to protect it from extreme gastric pH. The 
histological analysis of major organs including liver and kidney has been conducted. The 
histopathology showed no obvious damage of liver and kidney tissue in comparison with the 
control group (no treatment mice). The tissues exhibited normal morphological appearance, no 
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inflammatory reactions and necrosis were observed. The author claimed that the LDH-polymer 
hybrids without hepatotoxicity or renal cytotoxicity show beneficial for oral administration.165  
The biocompatibility of LDHs via jugular vein injection or intraperitoneal injections has been 
further studied to evaluate the LDH potential as an injectable drug delivery vehicle. Apart from 
the local irritation around tissues at the injection site which can be eliminated by meticulous 
intravenous technique, no systemic effects as indicated by clinical chemistry and 
histopathology were induced at administration doses of below 200 mg/kg. Therefore, the 
possibility of using LDH as an injectable drug delivery vehicle is suggested.166 
Exemplified from naturally occurring minerals, another predominant property of LDH 
nanoparticles over the others is that the compositions are highly compatible with normal 
physiological conditions as the byproducts (Mg2+, Al3+ or Al(OH)3, Cl-, H2O) also normally 
exist within the cells. All these unique properties have prompted LDHs to be an effective non-
viral agent as cellular drug and gene delivery vehicle.109 Most importantly, in 2014 and 2015, 
the results of four Phase I pharmacokinetic (PK) and gastroduodenal irritation clinical trials 
with LDH/Ibuprofen and LDH/naproxen demonstrate that these two products significantly 
reduce irritation in the gastrointestinal tract compared with current standard ibuprofen and 
naproxen. It is, therefore, highly expected that the LDH nanoparticles can be used as an 
efficient vehicle for drug/gene/protein delivery. 
2.4.4 Engineering of LDH nanoparticles  
To efficiently deliver therapeutic agents to the target area, the nanoparticle based delivery 
system are normally surface-modified to overcome the physiochemical and biological barriers, 
especially when administered systematically.167, 168 Numerous modification methods have been 
applied into nanoparticles engineering for improved colloidal stability, prolonged circulation 
time, target specificity and minimised side effects or immune response.169, 170 In the past 
decades, the modifications of LDHs have been mainly focused on the intercalation of guests 
into the galleries such as small organic anions, metal complexes, biological macromolecules, 
providing fascinating details about the physical/chemical properties of the galleries. However, 
the development of surface modification and applications LDHs as imaging tool are relatively 
lack of investigation.171, 172 The following part provides a review with respect to the engineering 
of LDHs for different biomedical applications.  
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2.4.4.1 Surface engineering for improved biomedical therapy  
The modification of nanoparticles, also known as nanotechnologies, is an important research 
area for fabricating hybrid nanoconjugates by combining advantages of one or more materials 
to obtain multiple functions. Such techniques need to make balance among physiochemical 
properties and the cost for best outcomes. The development of nanohybrids is considered to be 
one of the most important achievements in the nanomedicine progress.173 Many studies have 
successfully tailored LDHs based hybrid systems by integrating LDHs with the other materials 
such as organic or inorganic nanomaterials with improved properties for various biomedical 
applications as summarized below.   
Our previous research has successfully applied the serum coating strategy to stabilise LDHs in 
various electrolyte solutions. By adding the LDHs into albumin solution dropwise with 
vigorous stirring, LDHs are well stabilised at the albumin/LDH mass ratio of 5: 2.174 Thereby, 
our albumin pre-coating strategy has introduced a method for LDHs in vivo application. Also, 
such a pre-coating method provides for a way for LDH surface modification with ligands for 
targeting delivery, which will be interpreted applied in this thesis.  
Eudragit® L-100 and Eudragit® S-100 are two kinds of enteric methylacrylic acid and 
methylmethacrylate anionic copolymers. These polymers can be used as materials for oral 
treatment of inflammatory bowel diseases or specific colonic delivery as they are insoluble at 
pH lower than 5 but soluble at intestinal pH > 6 for Eudragit® L-100 and pH > 7 for Eudragit® 
S-100. Due to the intrinsic nature of LDHs, the anionic L-100 and S-100 can associate with the 
surface of LDHs, therefore, preventing the dissolution of LDHs at gastric pH while accelerating 
release of delivered therapeutic agents at the colon area. Liu et al. used S100 coated and 
sulfasalazine prodrug intercalated LDHs for paw edema inflammation treatment by oral 
delivery. The drug release from LDH composites at pH 1.2 restricted to 5-8% for 2 h, followed 
by approximately 20% drug release at the pH 6.8 for 2 h, and finally reached around 70% drug 
release at pH 7.4 for 10 h. Moreover, this newly designed nanoformulation exhibited 
effectively scavenging activity of superoxide radical in a concentration dependent manner, 
anti-inflammatory activity in an in vivo animal model resulted in reduction in the inflammation 
especially at day 4.165  
Xu et al. reported a well-dispersed SiO2 nanodot-coated LDHs (SiO2@LDH) via electrostatic 
interactions, which was developed into amine-functionalized LDH nanocomposite (NH2-
SiO2@LDH) by condensating (3-aminopropyl)triethoxysilane (APTES).  SiO2@LDH and 
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NH2-SiO2@LDH showed excellent colloidal stability either in culture medium or in the 
phosphate buffer. Further in vitro study showed that the nanocomposite exhibited low 
cytotoxicity, whereas the NH2-SiO2@LDH nanocomposite was much more efficiently in 
delivering siRNA into the U2OS cell line for cell proliferation inhibition as compared to the 
SiO2@LDH.175  
In vivo targeted delivery through LDHs is still lack of investigation especially in the 
development of RNA interference therapeutics. Choy et al. used the LDHs as Survivin siRNA 
delivery system to compare the passive and active tumour targeting ability in vivo by 
intraperitoneal injection. The targeted delivery system established by grafting LDHs external 
surface with amino silane and followed with folic acid conjugation. In vitro and in vivo results 
show that the LDH-FA/siSurvivin could avert biological barriers, enhance tumour-site 
accumulation and induce endosomal escape for targeting mRNA silencing in the cytoplasm. In 
vivo study with xenograft mice indicates that a 3.0-fold higher suppression of tumour volume 
than LDH/siSurvivin was achieved by LDH-FA/siSurvivin in vivo.176  
2.4.4.2 Modifying LDHs as imaging tools  
Medical imaging is an important technique for disease detection, prognosis and treatment 
intervention.177, 178 There are several imaging modalities including optical imaging, magnetic 
resonance imaging (MRI), ultrasound imaging, X-ray CT, positron emission tomography (PET) 
and single-photon emission CT (SPECT).179, 180 One or more imaging techniques can be used 
to give more precise prediction of disease development.181 The intrinsic properties of inorganic 
nanoparticles endow them great potential for medical imaging. By incorporating various 
imaging molecules or magnetic elements, these nanoparticles can be applied in nearly all 
imaging modalities. There is a retarded development of LDHs as imaging tools, which has been 
just exploited in recent years (Figure 2.9). However, as non-invasive 2D materials, LDHs are 
recognised as ideal candidates for imaging purposes owing to their biocompatibility and other 
properties essential to nanomedicine. 
In 2015, Lee et al. reported the charge effect on the distribution of LDHs by modifying LDHs 
surface with different organic groups and NIR fluorescent dye Cy5.5. By grafting the LDHs 
surface with amino acid and Cy5.5, the resulted positive amino-LDHs tends to accumulate in 
the lungs. The negatively charged LDHs modified with carboxylate groups cause susceptibility 
to rapid clearance from the blood circulation and mostly accumulated in the liver. It is 
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noteworthy that the neutral PEG5000 conjugated LDHs show enhanced blood circulation time, 
but no obvious fluorescence was observed in the major organs (Figure 2.9 A).182  
 
 
Figure 2.9 Schematic representation of (A) Fluorescent images of dissected organs from a 
mouse sacrificed after i.v. injection of Cy5.5-labeled LDH–NH2, LDH–NH–PEG5000 and 
LDH–NH–COOH for 3 h.182 (B) in vivo T1-images from a SD rat scanned at different time 
intervals of post-injection (dose: 3.1 mg or 197.1 mmol Gd/kg).183 (C) In vivo PET imaging in 
4T1 tumour-bearing mice shows stronger signal with 64Cu-LDH-BSA.185 (D) CT (a) and T1-
weighted MR images (b) of tumour after intravenous injection LDH-Gd/Au-heparin (dosage: 
72.4 mg Au/kg for CT imaging ; 3.0 mg or 190.8 mmol Gd/kg for MR imaging) in 4T1 murine 
breast tumour-bearing mice for 0 h, 1 h and 4 h.183 
In the disease diagnostic field, two or more strategies integrated into one system have attracted 
great interest. Xu et al. reported a CT/MRI dual-modality imaging and anti-cancer drug 
delivery LDH-Gd/Au nanocomposite based platform. Compared with the commercial CT 
contrast agent iobitridol and MRI contrast agent Magnevist, the nanocomposite has been found 
to be better CT and T1-weighted MRI contrast agents either in vitro or in vivo.  For breast 
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tumour imaging, the heparin, an anti-coagulant, was bind to the surface of LDH-Gd/Au surface 
for enhanced blood compatibility and blood circulation time. After 4-h intravenous injection, 
the CT and MR imaging signals increased to 80.2 and 5166.7 from original 28.9 and 4688.7, 
which are effective for tumour detection. Furthermore, the nanocomposite has been found to 
be able to cause cancer cells death after efficiently transport and release DOX into the cancer 
cell (Figure 2.9 B&D). This report provides the idea to construct multi-functional 
nanoplatforms for accurate cancer diagnostic and therapy in the early stage.183  
A report presented the LDHs PET imaging by labelling LDH nanoparticles with radioisotopes: 
bivalent cations 64Cu2+ and trivalent cations 44Sc3+. With BSA coating on the surface of LDHs, 
the 64Cu-LDH-BSA as found to prominently enrich in the tumour area with 7.7 ± 0.1%ID/g at 
16 h post-injection (Figure 2.9 C).184, 185 
 
2.4.5 Summary  
The biodegradable LDH systems hold great promise for gene and drug delivery. Especially, in 
vivo targeted delivery of drugs through LDH still remains as a key challenge. Currently, 
investigation on the in vivo application have attracted great interest. Intraperitoneal injection 
of LDH/siRNA to compare the passive and active tumour targeting ability in vivo was 
investigated by Choy et al.176 However, ideally, one would like to administer LDH-drug 
complexes via intravenous injection. Intravenous injection is the most rapid and effective 
injection route for therapeutic, especially for the central nervous system therapy.186 In the past 
few decades, the biomedical application research of LDHs mostly focused on the in vitro part. 
As shown in our previous work, when exposure to the electrolyte solution (physiological 
environment), the LDHs tend to aggregate probably due to adsorption of ions on the LDH 
surface in salt solution to counteract the intrinsic surface charge of LDHs. Therefore, the major 
challenges inhibited the LDHs to be used as drug/gene delivery platform for in vivo delivery 
is their tendency to aggregate in the physiological environment, which is supposed to be 
induced by their large positively charged surface area adsorbing proteins in the blood.187 The 
resulting large aggregates either block veins and capillaries or cause animals death, thus greatly 
restrict their in vivo application. Moreover, the adsorption of proteins to LDH surface is able 
to attract macrophages and dendritic cells, leading to immune system activation and 
nanoparticles clearance from the blood circulation.188 Therefore, the propensity to aggregate 
and bind serum proteins once in the bloodstream are major impediments for LDHs application 
in CNS delivery.  
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2.5 Hypotheses of this thesis  
 
Our studies provide strong evidence that LDHs possess the appropriate repertoire of chemical 
and physical properties essential for an effective, efficient and safe drug delivery vehicle for 
the CNS. We propose that precoating LDHs with albumin will greatly enhance their 
biocompatibility and biostability once in the bloodstream. The popular strategy used for 
efficient drug accumulation in the brain area is through ligand-receptor mediated endocytosis. 
Ideally, by simply conjugating the ligands to the albumin precoated LDHs, the LDHs stability 
and targeting ability for in vivo application could simultaneously obtained. We further propose 
that the conjugation of BBB-penetrating peptides will allow LDHs passage across the BBB. 
Since surface modification of LDHs progressed slowly, this project will focus on solving the 
remaining surface modification problem of LDHs for targeted CNS delivery. On the other hand, 
since magnetic nanoparticle provide imaging ability, therefore, in this study, we propose that 
the incorporating magnetic materials with LDHs enable brain tumour imaging and therapy 
simultaneously. 
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                 Chapter 3 
Materials and Methods 
 
 
This chapter summarizes the strategies utilised in the whole PhD project, including synthetic 
methods for various LDH formulations, techniques for material characterizations and 
biological evaluations.  
 
3.1 Materials synthesis 
 
3.1.1 LDH synthesis 
 
Figure 3.1 Schematic illustration of LDHs synthetic process 
 
The co-precipitation method was used to synthesise the pristine LDHs (Mg-LDHs or Mn-
LDHs). In this method, a solution containing two cations (i.e. Mg2+ / Mn2+ and Al3+) was added 
into an alkaline solution containing desired anion for co-precipitation to occur. Vigorous 
stirring and bubbling with nitrogen were performed to ensure homogeneity of the reaction 
mixture and minimise contamination from atmospheric carbon dioxide. The resulting LDHs 
mixture was then washed and hydrothermally treated under 100 Ԩ for 16 h to obtain 
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homogeneous LDH particles of good crystallinity (Figure 3.1).1 Mn-LDHs was well dispersed 
with help of ultra-sonication. The aging time and temperature affected the prepared particle 
size.   
3.1.2 Surface modification of LDH nanoparticles  
Uniform and well-stabilised LDH complexes were obtained by us through adding 2 ml of 4 
mg/ml LDH suspension into 2 ml of 10 mg/ml BSA solution (dissolved in deionised Milli-Q 
water) drop by drop under vigorously magnetic stirring for 30 mins. Furthermore, the BSA-
coated LDH (BSA-LDH) nanoparticles were then crosslinked by Glutaraldehyde (GTA) 
solution at a BSA: GTA molar ratio of 1:135 overnight to form crosslinked BSA-LDH (BSA-
LDH-GTA) (Figure 3.2). The surface modification enables LDH nanoparticle to be more 
colloidally stable and more easily dispersed in solution after freeze drying. The corresponding 
method developed by us. 
 
 
 
 
 
Figure 3.2 Schematic illustration of LDH nanoparticle coating with BSA coating (Step A) and 
subsequent GTA crosslinking (Step B).  
 
3.1.3 Peptide or dye conjugation with BSA  
We prepared peptide or dye conjugated BSA by activation of BSA with a 10-fold molar excess 
of sulfo-SMCC crosslinker first, producing maleimide-activated BSA. After excess non-
reacted crosslinker and by-products were removed, the maleimide-activated BSA reacts with 
the appropriate amount of peptide or dye having sulfhydryl groups. Usually, there are several 
or multiple maleimide-activations per protein/antibody molecule, enabling several peptide or 
dye molecules to be conjugated to each BSA molecule (Figure 3.3). 
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Figure 3.3 Two-step reaction scheme for conjugating peptide/dye with BSA proteins via Sulfo-
SMCC.  
3.1.4 Synthesis of ligand/dye modified LDHs  
This was done by simply mixing the BSA and BSA-peptide conjugate (with or without BSA-
dye conjugate) at a desired ratio using the similar coating and crosslinking recipe as above 
mentioned, as detailed in Figure 3.4. Thus, the ligand (and dye) modified LDHs were fabricated.  
 
 
Figure 3.4 Schematic illustration of LDH surface modification with targeting ligand and/or 
fluorescence dye. 
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3.2 Characterisation  
3.2.1 Powder X-ray diffraction (XRD)  
XRD is a powerful analytical tool for crystalline material structure identification. The powder 
specimen is finely ground, homogenised and placed into a thin layer of quarz sample holder 
with smooth surface. The sample holder was then inserted into the X-ray beam to generate 
characteristic X-ray spectra. Typically, the diffraction patterns were collected on the Rigaku 
Miniflex X-ray Diffractometer with Co Kα source (λ = 0.178897 nm) used. The sample rotates 
in the X-ray beam path at an angle θ while the X-ray detector that mounted on an arm rotates 
at an angle of 2θ. Data were collected at scanning range from 2o to 70o and a scanning rate of 
0.02o/s. In this way, all possible diffractions of the lattice should be obtained and the diffraction 
peaks could be converted into the d-spacings, characteristic of the mineral. The interaction of 
X-ray beam, diffraction angle, and the lattice spacing in the crystalline sample is demonstrated 
by the Bragg's Law: λ=2d sin θ. The pattern of LDH materials usually show a series of strong 
basal reflections conventionally indexed as 003, 006, etc.2,3 
3.2.2 MALDI-TOF mass spectra  
Matrix-assisted laser desorption/ionisation (MALDI) is a commonly used technique in mass 
spectrometry. Biomolecules and large organic molecules such as DNA, proteins, polymers, 
dendrimers and other macromolecules are ionized into fragments by conventional ionization. 
Typical MALDI methodology contains three-step process. The samples is first mixed with a 
suitable matrix and applied to a metal plate. Then the ablation and desorption of sample with 
the matrix are triggered by a pulsed laser irradiates. Finally, the analyte materials after 
ionization process are accelerated into the mass spectrometer that is used to analyse. The mass 
spectrometer used in this study was TOF (time of flight mass spectrometer). This study took 
advantage of accurate molecular weight measurement to characterise various BSA and 
modified BSA compounds by MALDI-TOF, so that the progress of chemical reactions were 
monitored (Chapter 5).4  
In this PhD studies, the spectra were recorded in a linear mode. For testing, a matrix thin layer 
of Sinapinic Acid saturated in EtOH was put on a ground steel target first and dried naturally. 
Then a sample solution (2 µl each) was premixed with an equal volume of matrix solution II 
(Sinapinic Acid saturated in TA30), and applied on the precoated ground steel target. Finally, 
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the number-average molecular weight (MW) and weight-average molecular weight (MW) were 
calculated from the MALDI-TOF spectra using Data Explorer software (Applied Biosystems, 
Framingham, MA). 
3.2.3 Particle size and size distribution  
Dynamic Light Scattering (DLS) was used to measure particle size. The movement of 
nanoparticles under Brownian motion have different speeds due to their different sizes where 
the scattered light from the particles was measured and converted into a size and a size 
distribution by the Stokes-Einstein relationship. The hydrodynamic particle diameter of LDH 
suspension was measured in the Nanosizer Nano ZS instrument (Malvern Instruments) at 25 °C. 
The LDH samples were dispersed in deionized water, PBS or cell culture medium.  
3.2.4 X-ray photoelectron spectroscopy  
X-ray photoelectron spectroscopy (XPS) was used to determine the amount of carbon (C), 
nitrogen (N), aluminium (Al), oxygen (O) and manganese (Mn) on the surface of Mn-LDHs. 
X-ray photoelectron spectra (XPS) were collected on a Kratos Axis ULTRA X-ray 
photoelectron spectrometer using a monochromatic Al KR (1486.6 eV) X-ray source and a 165 
mm hemispherical electron energy analyser. Signal from adventitious carbon was used as a BE 
standard at 284.6 eV.5 
3.2.5 Zeta potential analysis  
Microelectrophoresis was routinely used to calculate the Zeta potential of charged 
nanoparticles in solution. In this technique, a cell with a pair of electrodes at each side was 
used to contain the particle dispersion. When an electric field is applied to nanoparticle solution, 
the charged nanoparticles will move to the oppositely charged electrode and their velocity is 
measured and expressed in unit field strength as their mobility.6 The test was carried out by the 
Nanosizer Nano ZS instrument (Malvern Instruments) at 25 °C. The most known and widely 
used theory for calculating Zeta potential value was derived from calculation of the 
electrophoretic mobility using the Smoluchowski equation. The LDH samples were dispersed 
in deionized water, PBS or cell culture medium. 
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3.2.6 Scanning electron microscopy (SEM) / Energy-dispersive X-ray spectroscopy 
(EDS)  
SEM is technique used for examining the sample’s surface topography. Samples were prepared 
by suspending in H2O first and then attached to the conductive carbon film and finally dried in 
a vacuum oven at 70 °C before observation. The prepared samples were examined on a JEOL 
JSM 7800 FE-SEM with a narrow beam produced by the filament under an accelerating voltage 
of 5-30 kV. The morphological information of the specimen was obtained by secondary 
electrons caused by the hits of electron beam on the surface layers of subject.  
Energy-dispersive X-ray spectroscopy (EDS) is an analytical technique used for the sample 
elemental analysis or chemical composition characterisation. Each element has a unique atomic 
structure, which allows a unique set of peaks on its electromagnetic emission spectrum. 
Therefore, the EDS characterisation relies on the interaction of X-ray and sample. X-ray from 
a high-energy beam was used to stimulate the emission of X-ray from the specimen, and the 
change of electron state which is reflected as the X-ray energy in such a field was recorded by 
an energy-dispersive spectrometer. In this way, the EDS allows the elemental composition of 
the specimen to be measured.7  
In this thesis, the SEM of Mn-LDHs and EDS element mapping of Mn, Al and O were 
conducted to investigate the morphology and distribution of manganese within the Mn-LDHs. 
3.2.7 Transmission electron microscopy (TEM)  
Transmission electron microscopy (TEM) images were taken using a JEOL 1010 microscope 
operated at 100 kV. TEM is widely used in biology to examine subcellular structure at high 
resolution and structure in material sciences. In this technique, a transmitted optical image is 
formed by electrons from a highly focused monoenergetic electron beam in vacuum that 
penetrate the sample. To prepare material specimen, as-prepared LDH suspension was 
dispersed in 75% ethanol solution via ultrasonication for 1 h and transferred to a copper grid, 
then the image was taken at 100 kV. 
3.2.8 Fourier transform infrared (FTIR) spectroscopy  
FTIR was used in this study to identify the characteristic bonds in Mn-LDHs. The Mn-LDHs 
powder was finely mixed with KBr powder and 32-scan infrared (IR) spectra were collected 
on a Nicolet 6700 FTIR (Thermo Scientific, Thermo Fisher Scientific, MA, USA) over the 
range 4000-400 cm-1 at a resolution of 4 cm-1.   
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3.3 Biological techniques  
3.3.1 Agarose gel electrophoresis  
Agarose gel electrophoresis is a method used for separating a mixed population of 
DNAs/RNAs in a matrix of agarose. Under the electrophoresis conditions, the negatively 
charged DNA/RNA moves towards the positively charged anode and the speed of DNA/RNA 
travel through the gel is determined by their size and charge, and to lesser extent, their shape. 
In the nanomedicine field, migration of nucleic acids in agarose gel is retarded by the 
nanoparticles and the agarose gel electrophoresis technique used in this area is known as 
electrophoretic mobility shift assay (EMSA), which is used to separate the nanoparticle–
DNA/RNA and DNA/RNA mixture. As a common affinity electrophoresis technique used to 
study nanoparticle–DNA/RNA interactions, this technique is widely used to determine whether 
the nanoparticles are capable of binding a given amount of DNA. Normally, a corresponding 
lane where the pure DNA/RNA fragment without nanoparticles is used as control. Under 
designed experimental conditions, the interaction between the DNA/RNA and nanoparticle is 
stabilized, the free and retarded DNA/RNA on the gel reflects the bounding ability of 
DNA/RNA by nanoparticles.8 
For gel electrophoresis, the complexes were loaded into each well of 2% agarose gel and the 
corresponding amount of dsDNA was prepared in the absence of nanoparticles as control, 
which was then run in Tris-acetate-EDTA buffer at 80 V for 40 min. Genetic molecule bands 
were visualized using a GelDoc UV illuminator. In this thesis, gel electrophoresis analysis was 
performed to examine the binding ability of BSA-LDH-GTAs to genetic molecules. The 
association of dsDNA with BSA-LDH-GTAs was conducted by mixing dsDNA with pristine 
LDH, BSA-LDH, and BSA-LDH-GTA at the LDH: DNA mass ratio of 40:1 using light 
agitation at 37 °C overnight. 
3.3.2 Flow cytometry  
Flow cytometry is a common laser-based biophysical technique used for cell sorting, cell 
counting, biomarker detection, etc. In the nanomedince study, properties of individual particles 
or particles taken up by cells are able to be detected by light scattering or fluorescence emission. 
By suspending nanoparticles or cells in sheath fluid and passing them through an electronic 
detection apparatus, the fluorescence signal is generated and information about the 
nanoparticles or cells is provided. The scattered light collected by a lens in the forward direction 
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is called forward scatter channel (FSC). The FSC intensity is used to distinguish cellular debris 
and living cells. Side scatter (SSC) is light measured approximately at a 90o angle to the 
excitation line that provides information about the granularity or internal complexity. A 
combination of FSC and SSC can be used to differentiate different cell types in a heterogeneous 
sample.9   
In this thesis, BD LSR II flow cytometer was used to measure cellular uptake of nanoparticles. 
For testing, Cy3 as fluorescence marker was used to label DNA and premixed with BSA-LDH-
GTAs or ligand modified LDHs. Cells were seeded in multi-well plates at a certain density per 
well one day before the assay, followed by incubation with labelled LDH nanoaprticles for a 
few hours. After incubation, cells were washed 3 times with PBS and harvested by trypsination. 
After two more washes with PBS, the cells were re-suspended in paraformaldehyde (Merk) in 
PBS (PFA/PBS, 600 μl, 2 %) for FACS test. The results were analysed using FlowJo software. 
3.3.3 Confocal laser scanning microscopy (CLSM) 
Confocal laser scanning microscopy is an optical imaging technique used for collecting high 
resolution images based on selected depth (also known as optical sectioning). It enables three-
dimensional reconstructions of topologically complex objects. CLSM is able to cut the 
specimen into single planes and image these single planes along the optical axis (Z), the slices 
result in a 3D data set that provides information about the spatial structure of the object.  
In this thesis, a Carl Zeiss LSM 710 was used to examine cellular uptake and trafficking of 
LDH formulations.10 To prepare the specimen for CLSM, cells treated with various fluorescent 
labelled LDH formulations were grown on the coverslips. After incubation, the liquid was 
removed and cells were fixed with paraformaldehyde (Merk) in PBS (PFA/PBS, 600 μl, 2 %) 
for 20 mins, followed with three times wash with PBS. Finally the coverslip was mounted onto 
glass slides by fluoroshield with DAPI (Sigma). The slides were viewed using confocal 
microscopy. Z-series images were taken by using optical sectioning technique to observe the 
location of particles. 
3.3.4 MTT assay  
3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) assay is a simple 
method applied in nanomedicine area for evaluating their toxicity via measuring the 
mitochondrial dehydrogenase activity in living cells. The yellow tetrazolium MTT can be 
cleaved by mitochondrial dehydrogenases in metabolically viable cells, and the resulting purple 
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MTT formazan crystals can be dissolved and quantified by spectrophotometric means. As the 
toxicity extent affects the cells viability and apoptosis or necrosis leads to reduction in cell 
viability, therefore MTT is widely employed in the cytotoxicity study.11  
In this study, the stabilized BSA-LDH-GTAs and ligand modified LDHs toxicity to various 
cells were tested. Moreover, cell growth inhibition by delivering therapeutic drugs or siRNAs 
using LDH formulations as nanocarriers was tested in N2a and U87 cell lines. For testing, 
3000-5000 cells were seeded in each well of 96-well plates one day before the test, the tested 
complexes were dispersed in culture medium (supplemented with 10% FBS and 1% penicillin-
streptomycin) and incubated with cells for 24 to 72 hours at 37 °C. The cell viability was 
measured by adding MTT agent and reading the absorbance at 490 nm using a Synergy HT 
Microplate Reader. Results were compared to cells not exposed to corresponding nanoparticle 
complexes. 
3.3.5 In vivo confocal neuroimaging (ICON) technique  
In vivo confocal neuroimaging (ICON) technique uses the specially designed standard confocal 
laser scanning microscope (LSM 5 Pascal, Carl Zeiss AG, Jena, Germany) with a large probe 
space for positioning the animal and a long working distance objective lens. ICON is useful for 
repetitively visualising and analysing the passage of fluorescent carriers across the blood-retina 
barrier (BRB) in living animals in a real time manner, permitting to record the dynamic pattern 
of the fluorescent NP’s BBB-passage. As the retina is ontogenetically derived from the central 
nervous system (CNS) and the BRB is functionally identical to that of the BBB, thus the BRB 
is used as a model for the BBB.12-14  
In this study, the dynamic patterns of two-ligand modified LDH nanoparticles across the BRB 
in comparison with unmodified LDHs were collected by ICON.  
3.3.6 Fluorescence optical imaging  
Optical imaging is widely used for in vivo behaviour study of fluorescence containing system 
in small animal models. In the nanoparticle area, the fluorescent dyes can be physically 
encapsulated in nanocarrier systems or covalently conjugated with nancarriers, predicting drug 
release kinetics or monitoring nanoparticles biodistribution and site-specific accumulation in 
animal organs. To avoid the autofluorescence from natural biological tissues and obtain a high 
signal to noise ratio images, near-infrared (NIR) wavelengths above 700 nm where the 
autoflourescence emission is dramatically reduced are preferred.15,16 A silicon semi-conductor 
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material called as charge coupled device (CCD) is used for detecting light in this spectral region 
and converting it into the electrical signal.17  
The fluorescence optical imaging was used in this thesis for detecting the in vivo 
biodistribution of Cy7 labelled BSA-LDH-GTAs and comparing the brain targeting ability of 
ligand modified LDHs with that of unmodified LDHs.    
3.3.7 Hemolysis assay  
Hemolysis, also known as haemolysis, is the lysis of red blood cells and the release of their 
contents into surrounding fluid (e.g. blood plasma). Hemolysis may occur in vivo or in 
vitro (inside or outside the body). In nanomedicine area, the small size and unique 
physicochemical properties of nanoparticles may interact with erythrocytes, leading to 
potential toxicity. As hemolysis leads to symptoms such as anemia, jaundice and other 
pathological conditions, therefore, in vitro evaluation of biocompatibility of nanoparticles with 
blood samples is a necessary for early preclinical development.18  
In this thesis, the engineered various LDH formulations were evaluated by hemolysis assay. 
 
3.4 Summary  
The LDH formulations in the whole PhD project were characterised by the techniques 
mentioned above, ensuring the surface modification of LDHs were successful. For the in vitro 
and in vivo application, i.e. the biological stability and brain penetration ability, the engineered 
LDHs were evaluated by a series of biological techniques interpreted in this chapter. 
 
3.5 References  
 
1. Xu, Z. P.; Stevenson, G.; Lu, C.-Q.; Lu, G. Q., The Journal of Physical Chemistry B 2006, 
110 (34), 16923-16929. 
2. Poppe, L.; Paskevich, V.; Hathaway, J.; Blackwood, D., US Geological Survey Open-File 
Report 2001, 1 (041), 1-88. 
3. Auerbach, S. M.; Carrado, K. A.; Dutta, P. K., Handbook of layered materials. CRC Press: 
2004. 
Chapter 3 Materials and Methods 
57 
 
4. Hortin, G. L., Clinical chemistry 2006, 52 (7), 1223-1237. 
5. Kristensen, E. M.; Nederberg, F.; Rensmo, H.; Bowden, T.; Hilborn, J.; Siegbahn, H., 
Langmuir 2006, 22 (23), 9651-9657. 
6. Kaszuba, M.; Corbett, J.; Watson, F. M.; Jones, A., Philosophical Transactions of the 
Royal Society of London A: Mathematical, Physical and Engineering Sciences 2010, 368 
(1927), 4439-4451. 
7. Goldstein, J.; Newbury, D. E.; Echlin, P.; Joy, D. C.; Romig Jr, A. D.; Lyman, C. E.; Fiori, 
C.; Lifshin, E., Scanning electron microscopy and X-ray microanalysis: a text for biologists, 
materials scientists, and geologists. Springer Science & Business Media: 2012. 
8. Scott, V.; Clark, A.; Docherty, K., 1994. 
9. Ornatsky, O.; Bandura, D.; Baranov, V.; Nitz, M.; Winnik, M. A.; Tanner, S., Journal of 
immunological methods 2010, 361 (1), 1-20. 
10. Claxton, N. S.; Fellers, T. J.; Davidson, M. W., Encyclopedia of Medical Devices and 
Instrumentation 2006. 
11. Ferrari, M.; Fornasiero, M. C.; Isetta, A. M., Journal of immunological methods 1990, 
131 (2), 165-172. 
12. Steuer, H.; Jaworski, A.; Stoll, D.; Schlosshauer, B., Brain research protocols 2004, 13 
(1), 26-36. 
13. Steuer, H.; Jaworski, A.; Elger, B.; Kaussmann, M.; Keldenich, J. r.; Schneider, H.; Stoll, 
D.; Schlosshauer, B., Investigative ophthalmology & visual science 2005, 46 (3), 1047-1053. 
14. Voigt, N.; Henrich-Noack, P.; Kockentiedt, S.; Hintz, W.; Tomas, J.; Sabel, B. A., 
European Journal of Pharmaceutics and Biopharmaceutics 2014, 87 (1), 19-29. 
15. Pinkerton, N. M.; Zhang, S. W.; Youngblood, R. L.; Gao, D.; Li, S.; Benson, B. R.; 
Anthony, J.; Stone, H. A.; Sinko, P. J.; Prud’homme, R. K., Biomacromolecules 2013, 15 (1), 
252-261. 
16. Frangioni, J. V., Current opinion in chemical biology 2003, 7 (5), 626-634. 
17. Spibey, C. A.; Jackson, P.; Herick, K., Electrophoresis 2001, 22 (5), 829-836. 
18. Dobrovolskaia, M. A.; Clogston, J. D.; Neun, B. W.; Hall, J. B.; Patri, A. K.; McNeil, S. 
E., Nano letters 2008, 8 (8), 2180-2187. 
   
Chapter 4 Crosslinking to enhance colloidal stability and redispersity of LDH nanoparticles 
58 
 
                Chapter 4  
Crosslinking to enhance colloidal stability and 
redispersity of layered double hydroxide 
nanoparticles 
 
 
 
 
 
 
 
The present study introduces a strategy for stabilizing and redispersing layered double 
hydroxide (LDH) nanoparticles by crosslinking bovine serum albumin (BSA) coated onto the 
surface. The strategy involves optimization of the amount of the crosslinking agent 
glutaraldehyde (GTA) to achieve minimal aggregation and ready redispersion. LDH 
nanoparticles were prepared by co-precipitation and hydrothermal treatment, with subsequent 
bovine serum albumin (BSA) coating at the BSA/LDH mass ratio of 5:2. BSA coated onto 
LDH nanoparticles was crosslinked with different amounts of GTA. Aggregation studies using 
dilution assays, dynamic light scattering, and zeta potential analysis indicated that severe 
aggregation at lower LDH nanoparticle concentrations can be prevented by proper crosslinking 
of BSA with GTA. The GTA-crosslinked BSA-coated nanoparticles showed excellent 
redispersity compared to the non-crosslinked nanoparticles. In vitro cytotoxicity and cell 
uptake were found to be minimally affected by GTA-crosslinking. The new strategy therefore 
provides a much more effective method for the prevention of LDH nanoparticle aggregation 
and improved LDH nanoparticle redispersion for use in a wide variety of bio-applications in 
vitro and in vivo. This work has been partly published in Journal of colloid and interface 
science (2015). 
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4.1 Introduction 
 
Due to their potential application in biomedical therapeutics, nanoparticles have attracted 
intense scientific interest. Nanoparticles normally have at least one dimension in the range of 
1-100 nm, and can therefore readily enter the cell microenvironment. 1, 2 Stabilization of 
nanoparticles is a fundamental requirement necessary for successful use in clinical applications. 
Upon intravenous injection, nanoparticles often interact with biological environments that 
consist of biomolecules such as proteins, sugars, and electrolytes. These interactions can lead 
to nanoparticle aggregation and blockage of blood vessels and capillaries. Therefore, it is of 
particular importance that nanoparticles avoid aggregation in the in vivo situation.3-5 The 
development of nanotechnology allows researchers to rationally engineer nanoparticles for 
targeted delivery, prolonged circulation half-life, improved therapeutic index and reduced 
immunogenicity.6-8 It is therefore desirable to engineer nanoparticles with high colloidal 
stability in biological fluids. Additionally, maximal surface accessibility for drug/gene loading 
and delivery is desirable.  
Previously, we reported that layered double hydroxide (LDH) can effectively deliver 
drug/DNA into several types of cells including fibroblasts, HEK 293, CHO cells and neurons.9-
11 LDH is a family of anionic clays, and can be found in nature and also readily synthesized in 
the laboratory.  12, 13 Similar to hydrotalcite, the LDH composition can be expressed as the 
formula [M2+1–x M3+x(OH)2]x+(An–)x/n•mH2O, where M2+ represents a divalent metal cation, M3+ 
a trivalent metal cation, and An– an anion. The typical morphology of LDH nanoparticles is a 
hexagonal, plate-like, stacked layer structure, with a lateral diameter tailored from 50 to 300 
nm.14 With the exchangeable property, the LDHs are able to load various negatively charged 
therapeutics, such as DNA and RNA, anionic drugs and peptide/proteins. Many investigations 
show that LDHs are a potential drug and gene delivery candidate as they have many intrinsic 
advantages, including good biocompatibility, low cytotoxicity, high drug loading and 
controllable drug release mechanism.15-21 However, in vivo applications of these nanoparticles 
have been hampered by their tendency to aggregate in biological environments, resulting in 
inflammatory responses or death. Therefore, it is necessary to improve the stability of LDH 
nanoparticles for in vivo applications.  
Several methods have been used to increase stability of colloidal systems, including surfactant 
molecule attachment on the nanoparticle surface, surface modification of functional groups and 
modification designed to enhance stability such as steric repulsion and electrostatic repulsion.22 
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For example, silver nanoparticles were modified with two surfactants (sodium dodecyl sulfate 
and polyoxyethylenesorbitane monooleate-Tween 80) to improve anti-aggregation 
properties.23 PEGylation is an often used strategy to maintain colloidal stability via the steric 
effect.  22, 24, 25 It is well-known that charged nanomaterials adsorb strongly on oppositely 
charged surfaces, and they were widely used to stabilize the nanoparticles. Recently, we used 
BSA to coat LDH nanoparticles and found that these LDH-BSA complexes were colloidally 
stable in various electrolyte solutions.26 Chemical crosslinking is one of the highly versatile 
methods to create a network on the nanoparticle surface by crosslinking functional groups of 
the surface molecules. Crosslinking with the amine-carboxylic acid, isocyanate-OH/NH2 
reaction and Schiff base formation, 27, 28 can prevent aggregation via steric repulsion. 
 
 
Scheme 4.1 Schematic illustration of BSA-coating onto LDH nanoparticles and subsequent 
GTA crosslinking. 
 
Dynamic light scattering (DLS) is a common method to study aggregation and colloid stability 
of inorganic particles in the presence of oppositely charged macromolecules. For example, 
DLS studies pointed out that the ionic strength may induce conformational changes of the 
adsorbed items, therefore, the hydrodynamic thickness of the adsorbed layer on colloidal latex 
particles will increase. Surface charge neutralization of colloidal particles with the oppositely 
charged coating agents give rise to fast aggregation of the particles while the charge reversal 
enables stabilization of the system.  It is ideal to design a well-dispersed colloidal system over 
a wide range of buffer conditions with ready redispersity, while simultaneously having surface 
accessibility for loading therapeutics. Our previous stabilization of LDH nanoparticles with 
BSA was achieved in specific buffer conditions (Step A in Scheme 1), but the BSA-LDH 
complexes became unstable at low concentrations. Moreover concentrated BSA-LDH particles 
are poorly redispersed in aqueous solution. Therefore, in this study, we crosslinked BSA after 
coating onto the LDH surface with glutaraldehyde (GTA) (Step B in Scheme 4.1) and 
demonstrated that this crosslinked BSA-LDH system has an enhanced colloidal stability and 
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excellent redispersity. The optimized crosslinking only consumed a small portion of functional 
groups in BSA, leaving the majority available for further surface modification. Note that the 
crosslinked LDHs showed cytotoxicity similar to LDH alone, indicating their good 
biocompatibility for biomedical applications. 
 
4.2 Experimental section 
 
4.2.1 Synthesis of clay nanoparticles 
 
Materials 
Complementary strands of dsDNAs were purchased from GeneWorks and annealed at 75 °C 
for 10 min. One strand of the duplex was covalently coupled to the cy3 fluorophore at the 5′ 
end before annealing. Glutaraldehyde (GTA) solution (25%) was bought from Ajax Finechem, 
and other chemicals and reagents from Sigma-Aldrich if not illustrated specifically. Water used 
in experiments was deionized Milli-Q water. 
Synthesis of LDH nanoparticles 
Mg2Al-Cl-LDH (pristine LDH) was prepared using a co-precipitation-hydrothermal treatment 
method, as reported previously.17, 29 In brief, LDH was synthesized by mixing 40 ml NaOH 
solution (0.15 M) with 10 ml salt solution containing MgCl2 (3.0 mmol) and AlCl3 (1.0 mmol) 
under vigorous stirring. The resultant precipitate was washed and then hydrothermally treated 
at 100 oC for 16 h, giving an LDH suspension with the mass concentration of 4.0 mg/ml. 
 
4.2.2 BSA coating 
 
Crosslinking of BSA coated on LDH 
Two mililiters of 4 mg/ml LDH suspension was added into 2 ml of 10 mg/ml BSA solution 
(dissolved in deionized Milli-Q water) drop by drop under vigorously magnetic stirring for 30 
min to ensure saturated adsorption. The BSA-coated LDH (BSA-LDH) nanoparticles were 
then added with GTA solution at a BSA: GTA molar ratio of 1:0.5, 1:15, 1:45, or 1:135, and 
incubated overnight to form crosslinked BSA-LDH (BSA-LDH-GTA).   
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Quantification of active amino groups on crosslinked BSA  
GTA was applied as the crosslinking agent to react with BSA (as shown in Scheme 4.2). The 
determination of unreacted amino groups was performed using the reaction of TNBS (2, 4, 6-
trinitrobenzene sulfonic acid) with free amino groups. As a simulation, BSA (50.0 mg) was 
dissolved in 10.0 ml reaction buffer (0.1 M sodium bicarbonate, pH 8.5). Aliquots of 1.0, 2.5, 
5.0, 10.0, 20.0, 30.0, 60.0, 80.0 and 100.0 µl of 5% GTA solution were added gradually to 1.0 
ml BSA solution and the total volume was adjusted with the reaction buffer to a total 2.0 ml. 
After 24 h incubation at 20 °C under constant shaking, 1.0 ml 0.01% TNBS solution was added 
into the reaction mixture and shaken at 500 rpm for 2 h at 40 °C. The solution was then assayed 
by recording the absorbance at 343 nm.  The content of free amino groups on the crosslinked 
BSA surface was calculated in relation to BSA treated in the same manner as described above 
but without using GTA. 
 
 
 
 
Scheme 4.2 Schematic illustration of BSA reaction with GTA 
Colloidal stability test 
The size and polydispersity index (Pdi) of BSA-LDH and BSA-LDH-GTA at different 
concentrations (diluted for 0, 10, 160, and 320 times) were measured on a Nano Zetasizer 
(Nano ZS, MALVERN Instruments). The same volume of PBS was then mixed with BSA-
LDH or BSA-LDH-GTA under vigorous stirring for 30 min and the particle size distribution 
was monitored similarly. LDHs in water and in PBS were also measured for the particle size 
distribution on a Nano Zetasizer instrument. 
 
Redispersion ability test  
After centrifugation, BSA-LDH or BSA-LDH-GTA was collected and frozen in liquid nitrogen 
for 10 min, and then freeze-dried for 24 h, followed by being redispersed in water under gentle 
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ultrasonication. The particle size distribution of water-redispersed particles (equilibrate to the 
original concentration) was measured and then compared with the initial one in the suspension.  
 
Nucleic acid association with LDH 
 
The association of dsDNA with LDH was conducted by mixing dsDNA with pristine LDH, 
BSA-LDH, and BSA-LDH-GTA at the LDH: DNA mass ratio of 40:1 using light agitation at 
37 °C overnight.  
 
4.2.3 Characterisation of different LDHs 
 
The particle size distribution and zeta potential of LDH, BSA-LDH, and BSA-LDH-GTA in 
aqueous solutions were measured on a Nano Zetasizer instrument. Transmission electron 
microscopy (TEM) images were obtained on a JEOL 1010A transmission electron microscope 
at an acceleration voltage of 100 kV. Powder X-ray diffraction (XRD) patterns were recorded 
on a Rigaku Miniflex X-ray Diffractometer using Co Kα source (λ = 0.178897 nm) at a 
scanning rate of 0.02o/s (2θ) from 2θ = 2o to 2θ = 80o. Fourier Transform Infrared (FTIR) 
spectra were recorded on a Nicolet 6700 spectrometer by accumulating 32 scans at a resolution 
of 4 cm-1 in the attenuated total reflection model.  
 
4.2.4 In-vitro and in-vivo assays 
 
In vitro cytotoxicity test and cellular uptake  
Rat vascular smooth muscle cells (SMC) and human breast tumour cell line (MCF-7) were 
seeded in a 96-well or 6-well plate at a density of 4-5 × 104 cells/cm2 in growth medium 
(Medium 199 and DMEM medium respectively, containing 10% foetal calf serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin), and incubated at 37 °C in a humidified atmosphere 
with 5% CO2. 
Cytotoxicity of BSA-LDH-GTA was examined by the MTT (Sigma) assay. Twenty-four hours 
after seeding, the cells were treated with growth medium containing BSA-LDH-GTA (LDH 
10, 50, 100, 200 or 500 µg/ml). The control cells were treated with growth medium only. After 
24, 48 and 72 h incubation, 20 μl of 5 mg/ml MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl 
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tetrazolium bromide) solution was added, and then incubated at 37 °C for 4 h. Culture medium 
was then removed, and formazan crystals within cells solubilized by incubation with 0.2 ml 
DMSO for 10 min. Absorbance was measured at 490 nm on a SpectraMax M5 microplate 
reader, and cell viability calculated as (absorbance in the treatment well)/(absorbance in the 
control well) × 100%.  
Cell uptake efficacy of BSA-LDH and BSA-LDH-GTA was determined by flow cytometry 
(BD LSM II). Twenty-four hours after cell seeding, the cells were treated with growth medium 
containing BSA-LDH-dsDNA-cy3 or BSA-LDH-dsDNA-cy3-GTA for 24 h (both contained 
the same amount of dsDNA-cy3). After centrifugation and washing with PBS for three times, 
the cells were fixed in 2% paraformaldehyde/PBS and analyzed on the flow cytometer.  
In vivo fluorescence imaging 
 
The feasibility of current surface modification for in vivo application was investigated. Cy7 
labelled BSA-LDH-GTAs were prepared. Firstly, BSA was conjugated with excess amount of 
Cy7 through bifuncitonal Sulfo-SMCC and purified to get rid of free cy7. Then 10% BSA was 
substituted by BSA-Cy7 to ensure sufficient fluorescence absorbed, following the coating and 
crosslinking procedures described above, Cy7 labelled BSA-LDH-GTAs were obtained. The 
resulted nanoparticles were subjected to centrifugation and washed by milli-Q water to remove 
the excess BSA-Cy7. In vivo optical imaging experiments were performed on an In Vivo MS 
FX Pro instrument (Bruker Corporation). Cy7 images were collected with a 730 ± 20 nm 
excitation and 790 nm ± 20 nm emission filter set (f-stop 2.80, 4 × 4 binning, 120 mm FOV, 
20 s exposure time). All images were batch exported as 16-bit TIFF images and images were 
processed by Image-J (National Institutes of Health) software. Fluorescence images were false 
coloured. 
 
4.3 Results and Discussion 
 
BSA-coated LDH nanoparticles and redispersity  
As shown in Figure 4.1A and Figure 4.S1, after hydrothermal treatment, a monodispersed LDH 
nanoparticle suspension was obtained with an average hydrodynamic diameter of 105 nm and 
a Pdi of 0.211, in agreement with the previous report.30 When the LDH suspension was added 
into electrolyte solution (e.g. PBS or culture medium), LDH nanoparticles formed aggregates 
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with the average particle size being in the micrometer range (>1000 nm) in PBS (not shown) 
and 400 nm in culture medium (Figure 4.1A), respectively. Our previous work has 
successfully developed a BSA coating method to prevent aggregation of LDH nanoparticles in 
PBS or culture medium at BSA/LDH mass ratio of 5:2 where there were  maximum 0.7 mg 
BSA adsorption on 1.0 mg LDH while there were 3.6 mg of free BSA in 1.0 ml aqueous 
suspension.26 As shown in Figure 4.1A, the particle size distribution of BSA-LDH (5:2) in PBS 
or culture medium was similar to that of BSA-LDH originally suspended in water. These 
phenomena showed that coating LDH with BSA was able to prevent aggregation of LDH 
nanoparticles in electrolyte solutions. As we previously reported, the aggregation was probably 
due to the bridging effect of adsorbed serum from the medium or reduced electrostatic 
repulsion caused by adsorption of ions on the LDH surface that counteracts the intrinsic surface 
charge of LDHs. We believe that BSA coating probably provides a strong steric repulsion and 
is able to prevent LDH particle aggregation in electrolyte solutions and the culture medium. 
 
 
Figure 4.1 (A) Particle size distribution of LDH and BSA-LDH (5:2) in water, PBS or culture 
medium. Note: the size of LDH in PBS was over the measurement limit of Nanosizer and not 
shown here; (B) Particle size distribution of redispersed BSA-LDH after freeze-drying. Each 
experiment was carried out in 3 independent experiments. 
Figure 4.1B shows the redispersion ability of BSA-LDH after centrifugation and freeze-drying 
compared with the initial BSA-LDH suspension. The data revealed that the redispersed BSA-
LDH had many large aggregates with the size > 1000 nm, different from that in BSA-LDH 
suspension (average particle size of 171 nm). The BSA-LDH suspension contains many free 
BSA molecules, which are in adsorption equilibrium with the BSA adsorbed on the LDH 
surface, thereby maintaining colloidal stability. Freeze-drying following centrifugation 
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removes the free BSA from solution, preventing equilibrium being reached again during 
redispersion, resulting in incomplete dispersion. As freeze-drying techniques are an essential 
process in the manufacture pharmaceuticals, it is of great importance to enhance the 
redispersion ability of BSA-LDH complexes.   
Colloidal stability of BSA- coated LDH nanoparticles 
As shown in Figure 4.2, BSA-LDH (the BSA/LDH mass ratio = 5:2, the LDH concentration = 
2000 µg/ml) had an average size of 176 nm and a Pdi of 0.229. When this BSA-LDH 
suspension was diluted 10 times (the LDH concentration = 200 µg/ml), the particle size 
distribution of BSA-LDH remained the same (the average size = 173 nm, and Pdi = 0.230). 
However, when the BSA-LDH suspension was continuously diluted, the particle average size 
increased to 298 nm (the LDH concentration = 12.5 µg/ml) and then 864 nm (the LDH 
concentration = 6.3 µg/ml). This aggregation can be again explained by the disturbed 
equilibrium between BSA adsorbed on LDH and free BSA in solution after dilution. With the 
addition of water, the concentration of free BSA in solution decreases and some adsorbed BSA 
desorbs from the surface to solution. As BSA desorption continues, LDH particles would share 
BSA molecules via the protein bridging effect, which leads to particle aggregation.      
 
   
Figure 4.2 Particle size distribution of BSA-LDH (mass ratio of BSA: LDH = 5:2) at 
different concentrations. Each experiment was carried out in 3 independent experiments. 
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Enhanced colloidal stability by crosslinking BSA on the LDH surface 
We next employed a crosslinking strategy to increase BSA-LDH stability and redispersity. 
First, the effectiveness of crosslinking BSA by using GTA was examined. The amount of 
unreacted amino groups deceased significantly with increasing GTA amount used (Table 4.1 
and Figure 4.S2), indicating that there was a progressive degree of crosslinking.31 After 
addition of 40 µl 5% GTA or more, very little change in the unreacted amino group number 
was observed, indicating that all available amino groups had participated in the GTA 
crosslinking.  
 
Table 4.1 Free amino group in each BSA molecule after glutaraldehyde cross-linking. The 
number of amino groups on the crosslinked BSA was determined. GTA volumes of 1 to 100 
µl for quantitative cross-linking of the 59 amino groups in the BSA molecules were employed 
in these tests.  
5% Glutaraldehyde volume 
(µl) 
Amino groups per BSA molecule 
           Mean               S.D.          
1                                                               37.24              1.30 
2.5                                                            34.93              0.58 
5                                                               33.04              1.42 
10                                                             18.76              0.31 
20                                                              6.09               0.57 
30                                                              2.51               0.52 
40                                                              1.77               1.29 
60                                                              1.79               0.72 
80                                                              2.01               0.53 
100                                                            1.71               1.43        
 
 
To determine the optimized GTA concentration for stabilizing the BSA-LDH nanohybrids, a 
series of BSA: GTA molar ratios (1:0.5, 1:15, 1:45, and 1:135) were used and the obtained 
suspensions were subjected to dilution tests. As shown in Figure 4.3A and Table 4.S2, the 
average particle size of BSA-LDH-GTA was around 170 nm at the BSA/GTA ratio of 1:135 
when diluted from 40 to 640 times. In all other cases (BSA: GTA molar ratio = 1:0.5, 1:15 and 
1:45), the average particle size increased, indicating that some aggregation still took place even 
though the adsorbed BSA molecules were partly crosslinked. Therefore, the molar ratio of BSA: 
GTA (1:135) was applied in the following experiments. 
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  Figure 4.3 (A) The average particle size of BSA-LDH-GTA at different BSA: GTA molar 
ratios and dilution times; (B) The particle size distribution of BSA-LDH-GTA (the BSA: GTA 
molar ratio = 1:135) at different concentrations. Each experiment was carried out in 3 
independent experiments. 
The particle size distribution of BSA-LDH-GTA (1:135) also remained the same after 10-, 160- 
and 320-fold dilution (Figure 4.3B), in sharp contrast with that presented in Figure 4.2. This 
suggests that the crosslinking of surface adsorbed BSA by GTA can avoid/minimize the release 
of adsorbed BSA into solution, thus preventing LDH particles from aggregation caused by 
dilution. Interestingly, the BSA: GTA molar ratio of 1:135 corresponded to 5 µl 5% GTA 
(Table 4.1), which means that there were 33 amino groups available per BSA molecule after 
crosslinking. Therefore, the optimized BSA/GTA molar ratio of 1:135 ensures sufficient 
colloidal stability of the LDH nanoparticle system, and at the same time maintains an adequate 
number of free amino groups/BSA for further modification and/or loading.  
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Figure 4.4 The average particle size of BSA-LDH or BSA-LDH-GTA at different LDH 
concentrations in water and PBS. Each experiment was carried out in 3 independent 
experiments. 
As shown in Figure 4.4 and Table 4.S2, the average size of the initial BSA-LDH particles in 
water or PBS remained at about 175 nm when the suspension was diluted up to 80-fold, but 
increased dramatically when diluted 320-fold. In contrast, BSA-LDH-GTA nanohybrids 
remained the same size (around 180 nm) in both water and PBS when diluted. This stability 
can be attributed to the crosslinking of BSA, which immobilizes BSA onto the LDH surface 
and maintains the colloidal stability through steric repulsion. The comparison clearly 
demonstrates the enhancement of BSA-LDH colloidal stability through the crosslinking 
strategy.  
Improved redispersity of BSA-LDH after crosslinking 
 
Figure 4.5 Particle size distribution of BSA-LDH-GTA and redispersed one. Each experiment 
was carried out in 3 independent experiments. 
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As shown in Figure 4.5 and Table 4.S1, the redispersity of freeze-dried BSA-LDH-GTA 
hybrids was obviously improved. After BSA-LDH-GTA hybrids were redispersed with gentle 
ultrasonication, the particle size distribution with an average particle size of 219 nm and a Pdi 
of 0.323 was very similar to that for the parent BSA-LDH-GTA hybrid. This redispersity is 
markedly better than that for un-crosslinked BSA-LDH (Figure 4.1B) under the same 
conditions.  The crosslinked BSA on the LDH surface was now immobilized with a more rigid 
configuration, which may keep the freeze-dried particles better separated. As a result the BSA-
LDH-GTA hybrids were more readily redispersed in water. This property is of importance to 
the pharmaceutical sector, because freeze-drying technique are essential for the storage and 
transport of pharmaceuticals.  
Cytotoxicity of BSA-LDH-GTA  
 In general, the viability of cancer cell line, MCF-7, and smooth muscle cells (SMCs) after 
exposure to BSA-LDH-GTA (Figure 4.6A, B) gradually decreased with increasing particle size 
concentration and the incubation time.29 The viability of SMCs treated with 10-100 µg/ml 
BSA-LDH-GTA did not change significantly after the first day of incubation, but decreased by 
20 to 30% at day 2 to 3. However, a significant reduction in cell viability was observed in BSA-
LDH-GTA at the concentrations of 200-500 µg/ml of BSA-LDH-GTA at day 2-3.  
BSA-LDH-GTA at 10-200 µg/ml did not affect the MCF-7 cell viability significantly during 
the 3-day incubation period (> 80%), while 500 µg/ml significantly reduced their viability after 
2 to 3 days. Compared with LDH’s cytotoxicity reported previously (cell viability were over 
than 90% within 3 days incubation at the concentration range of 10-500 µg/ml),32 BSA-LDH-
GTA were slightly more toxic to SMCs, suggesting good biocompability. The increased 
cytotoxicity is possibly due to the unreacted aldehyde groups in GTA that are known to induce 
some toxicity.33  
In most in vitro tests for drug and gene delivery,30, 34, 35 the LDH concentration is normally in 
the range of 10-100 µg/ml. Thus this toxicity test has demonstrated that the BSA-LDH-GTA 
delivery platform has negligible toxicity for SMCs and the cancer cell line MCF-7 in our in 
vitro assay. 
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Figure 4.6 Cell viability of SMCs (A) and MCF-7 (B) after treated with BSA-LDH-GTA (BSA: 
GTA molar ratio = 1:135) at concentrations from 0 to 500 µg/ml. Statistics; each experiment 
was carried out in duplicate and 3 independent experiments were performed. The data are 
presented as the mean ± SEM. One-way ANOVA with Bonferroni’s post-hoc test was used to 
assess statistical significance. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.   
 
 Cellular uptake 
                 
Figure 4.7 Histogram showing (A) the percentage of SMCs cells internalizing BSA-LDH or 
BSA-LDH-GTA and (B) the percentage of MCF-7 cells internalizing BSA-LDH or BSA-
LDH-GTA monitored by flow cytometry. Statistics; each experiment was carried out in 
duplicate and 3 independent experiments were performed. The data are presented as the mean 
± SEM.  T-test was used to assess statistical significance. * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001.   
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According to our previous report, a five-fold excess of LDH nanoparticles is sufficient to 
ensure maximum association of dsDNA with LDHs.36 The conditions required for the same 
amount of dsDNA intercalation were confirmed by gel electrophoresis (Figure 4.S3). Therefore, 
the LDH: dsDNA mass ratio of 40:1 was used to ensure BSA-LDH and BSA-LDH-GTA to 
contain the same amount of dsDNA. 
 
As shown in Figure 4.7, after 24 h incubation, the percentage of SMCs internalizing fluorescent 
BSA-LDH-dsDNA-cy3-GTA particles was about 67%, 30% lower than that for cells 
internalizing BSA-LDH-dsDNA-cy3 (96%). MCF-7 cells took up 17% less BSA-LDH-
dsDNA-cy3-GTA particles (68%) than BSA-LDH-dsDNA-cy3 (85%). The results indicate that 
GTA crosslinking inhibits cell uptake efficiency to some degree compared to uncrosslinked 
nanoparticles. The possible reason is loss of functional positive amino groups on the surface of 
BSA-LDH nanoparticles after crosslinking. The positive charges on the particle surface 
increases cell surface affinity. As previously reported, increasing the amount of amine groups 
facilitates cellular uptake of nanoparticles for various cell lines.37 Although BSA-LDH-GTA 
showed slight inhibition to cell uptake compared to BSA-LDH, the GTA crosslinking strategy 
provides much higher colloidal stability and much easier redispersity of LDH nanoparticles for 
more potential bioapplications in vivo. 
 
In order to further confirm the stability of BSA-LDH-GTAs in in-vivo assay, intravenous 
injection of BSA-LDH-GTA nanoparticles into the tail vein of mice, optical imaging 
experiments were conducted to study the biodistribution behaviour of the nanoparticles in vivo 
over a long imaging times. In this study, fluorescence images of the belly and the back side of 
the mice were taken to display organ signals at the respective areas in the body. Figure 4.8A 
shows the fluorescence intensity of the optical imaging agent within the mice over a 48 h time 
course. Ex vivo study at 24 h and 48 h (Figure 4.8B) were used to validate the information 
obtained from the in vivo images. High fluorescence signal for BSA-LDH-GTA nanoparticles 
were observed in organs such as the liver, gut, kidney and spleen which are responsible for 
clearance and excretion. The distribution in the RES system other than the non-RES system 
was likely a direct consequence of activation of the RES clearance mechanism for the particles. 
Besides, the size of the current nanoparticles may also contribute to the accumulation in the 
liver area, as it was evidenced in many reports that the particles with around 50-200 nm tend 
to arrive at fenestration in the hepatic sinusoidal endothelium after intravenous injection.38, 39  
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Figure 4.8 In vivo fluorescence mice image (front and back side) of BSA-LDH-GTA at 0.5, 
2, 5, 24, and 48 h time courses. (II) Fluorescence intensity of organs 24hr and 48 hr post 
injection.  
As can be observed in the Figure 4.8A, the fluorescence signal in the kidney area and bladder 
region can be detected following injection, implying that part of the nanoparticles experienced 
clearance by renal excretion. As the size of current nanoparticles have been above the renal 
threshold and are not able to be cleared by the kidneys, therefore, the BSA-LDH-GTAs may 
experience dissolution during the circulation as there was continue decrease in this signal 
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during 48 h. As for in vivo fluorescence imaging, the signal are always interfered by 
autofluorescence generated by the mice body itself, therefore, in this study a fluorophore Cy7 
that can be excited in the 600–900 nm range was exploited since the biological tissues are 
relatively transparent in this spectral region.40, 41 In-vivo and ex-vivo biodistribution results 
together indicate the feasibility of Cy7/BSA-LDH-GTAs stability for in vivo study and the 
clearance was through multiple pathways from the body. Thus, the current LDH engineering 
method with simpler conjugation process and purification procedures is flexible and adaptable 
for in vivo application through intravenous injection. 
4.4 Conclusion  
 
Size control of LDH nanoparticles is a challenging problem for clinical applications. This work 
introduced a crosslinking strategy to stabilize LDH nanoparticles based on the previous BSA 
coating strategy. As crosslinked BSA-coated LDH hybrids had improved colloidal stability and 
redispersity of freeze-dried samples. Although the cytotoxicity of BSA-LDH-GTA increased 
especially at the concentration of 500 µg/ml when compared to LDH cytotoxicity, the 
cytotoxicity of BSA-LDH-GTA at concentrations of 10-200 µg/ml had minimal effect. 
Importantly, our modified LDH nanoparticles can be further conjugated with functional 
molecules to promote target delivery to specific cells types, therefore, in the cell, drug or gene 
could be released from the NPs via change with electrolytes and dissolution of LDH in acid 
conditions and accumulated in the target cells. Overall, this new crosslinking strategy promises 
a more stable BSA coated LDH nanoparticles system with broad applications in vitro and in 
vivo. As for in vivo fluorescence imaging, the signal are always interfered by autofluorescence 
generated by the mice body itself, therefore, in this study a fluorophore Cy7 that can be excited 
in the 600–900 nm range was exploited since the biological tissues are relatively transparent in 
this spectral region.40, 41 In-vivo and ex-vivo biodistribution results together indicate the 
feasibility of Cy7/BSA-LDH-GTA stability for in vivo study and the clearance was through 
multiple pathways from the body. Thus, the current LDH engineering method with simpler 
conjugation process and purification procedures is flexible and adaptable for in vivo 
application through intravenous injection. 
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Supplemental information 
 
The redispersion ability and size distribution of GTA cross-linked and BSA pre-coated LDH 
nanoparticles were tested in order to study their potential application as drug/gene carriers. 
From the PCS measurements, the mean diameter of the LDH nanoparticles was around 100nm, 
with a monodispersed size distribution. The particle size of the nanoparticles was greatly 
increased when the BSA was coated. Table S1 shows that the size of the BSA-LDH 
nanoparticles almost has no change after cross-linked by GTA. However, the zeta potential 
decreased that might due to the losing of amino groups. 
 
Table 4.S1 Particle average dimension (nm) of BSA-LDH and BSA-LDH-GTA   
Sample   
Size (d.nm)/Pdi       Zeta potential (mV)       redispersed 
LDH                                           105.2/0.211                 35.0                               -            
                                                                 
BSA-LDH                                  171.1/0.198                -22.9                        ˃2000/1.0          
                     
BSA-LDH-GTA                         174.7/0.195               -25.8                         219/0.323    
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As shown in Figure 4.S1, after hydrothermal treatment, a nanodispersed LDH nanoparticles 
suspension was obtained. The nanoparticles are well-dispersed with narrowly distributed 
hydrodynamic diameter of 90-110 nm by PCS.  
The average diameter measured by PCS is in accordance with the TEM image (90-150 nm) 
where the morphology of such prepared LDH nanoparticles is monodispersed and well 
hexagonally shaped as shown in Figure 4.2B which is consistent with previous report.34 
 
 
Figure 4.S1 A) Particle size distribution of LDHs; B) TEM images of LDH nanoparticles; C) 
FT-IR spectrum of LDH nanoparticles; D) XRD pattern of LDH nanoparticles. 
 
LDH FTIR spectrum shows some peaks commonly appearing in MgAl-LDH spectra: (1) the 
intense broad band around 3400-3500 cm-1 associated with stretching vibration of O-H in the 
brucite-like layer and water molecules; (2) the sharp band at 1363 cm-1; (3) the peak at 447 cm-
1, particularly characteristic of Mg2Al-LDH materials.17, 34 
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XRD shows the pattern of the LDHs are typical of lamellar materials, characterized with basal 
reflections, associated harmonics at low 2θ angles and weaker nonbasal reflections at higher 
angles. The LDH is well-crystallized, as reflected by the sharp (003) and (006) basal reflections 
as well as (009) peaks. 
 
Table 4.S2 Crosslinking effects on BSA-LDH system stability in PBS at different 
concentrations 
 
  
 
Figure 4.S2 Crosslinking of BSA with different amounts of GTA: amino group content in the 
solution of the BSA in correlation to the amount of GTA added. GTA volume between 1.0 and 
100 µl of the theoretic amount for quantitative cross-linking of the 59 amino groups in the BSA 
molecule were employed. 
 
Dilution times 
BSA-LDH BSA-LDH-GTA 
In water (nm) In PBS (nm) In water (nm) In PBS (nm) 
0 175.5 184.7 175.5 184.7 
5 172.5 173.2 170.5 172.9 
160 215.8 252.3 170.1 178.4 
320 863.9 259.9 170.5 186.7 
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Figure 4.S3 Gel retardation assay of complexes of dsDNA with LDH, BSA-LDH, BSA-LDH-
GTA at weight ratios 40:1 (LDH/dsDNA). 
As shown in Figure 4.S3, the same dsDNA loading amount was achieved at a mass ratio of 
40:1 (40 mg LDH: 1 mg dsDNA) when intercalation was carried out at 37 °C for overnight 
(Figure 4.S3).  Therefore, in the following cell uptake assay, weight ratios 40:1 (LDH/dsDNA) 
was used to ensure BSA-LDH and BSA-LDH-GTA contain same amount of dsDNA. 
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                    Chapter 5 
Surface functionalization of stabilized layered 
double hydroxide nanoparticles with ligands: 
benefit of adding targeting ligands via bovine 
serum albumin 
 
 
 
 
 
 
 
 
 
In this section, non-viral layered double hydroxide nanoparticles (LDHs) were modified as a 
target delivery system. Two brain tumour targeting ligands, i.e. angiopep-2 (Ang2) and rabies 
virus glycoprotein peptide (RVG), were conjugated to the LDHs, respectively, through inter-
matrix bovine serum albumin (BSA), rendering the LDHs simultaneously excellent colloidal 
stability and targeting capability. Two ligands were first conjugated with BSA through 
crosslinker sulfo-SMCC, respectively. Following our previous BSA coating and 
glutaraldehyde (GTA) crosslinking strategies, we successfully developed an approach to 
prepare colloidally-stabilised tumour-targeted LDH nanoparticles. The targeting efficacy of 
ligand-conjugated LDH delivery system was demonstrated in the uptake by two brain tumour 
cells (U87 and N2a) compared to unmodified LDHs, while the cellular uptake mechanism was 
similar. Importantly, ligand modified LDHs demonstrated increased anti-proliferation 
compared with unmodified LDHs. This new approach may contribute to rational design of 
targeted nanoparticles, showing great potential as a promising platform for selective and 
effective therapeutic treatment of neural diseases.   
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5.1 Introduction 
 
Nanomaterials and colloidal drug delivery systems are believed to preferentially accumulate in 
the tumour area due to enhanced permeation and retention (EPR) effect.1 To grow quickly, the 
tumour cells tend to stimulate blood vessel formation which is called angiogenesis. Such 
neovasculature with the abnormal form and architecture leads to leakage of vessels and 
dyfunctional lymphatic drainage, therefore, nanocarriers can extravasate into the tumour site 
via the defective vessels by the EPR effect.2,3 However, the challenge is confounded by the fact 
that nanoparticles ubiquitously intercellular distribution within a tumour may fail the cancer 
treatment due to suboptimal cellular uptake efficacy.4 Efficient and specific cell uptake is the 
priority for optimising treatment. Normally, cancer cells have expressed a number of receptors, 
which uniquely interact with specific ligands. Comparatively, decorating the nanopaticulate 
system with a specific targeting ligand is expected to promote the cell internalisation rate after 
extravasation and ultimately improve therapeutic efficacy. Moreover, active targeting greatly 
reduces the random distribution in the healthy tissue, thereby reducing undesired systemic side 
effect.5  
Layered double hydroxides (LDHs), also known as anionic clays or hydrotalcite-like materials, 
are a class of two dimensional synthetic lamellar compounds that are made up of positively 
charged layers with an interlayer region containing charge-balanced anions and water 
molecules. The structure is brucite-like (Mg(OH)2), where the hydroxyl anions are hexagonally 
closely packed with divalent magnesium cations filling all octahedral sites. Consequently, each 
magnesium cation is surrounded by six hydroxyl groups to form an octahedron, and octahedra 
share edges to form an infinite 2-D layer. The brucite layers are held together by weak hydrogen 
bonds and stacked on top of one another. Part of the cations can be isomorphically replaced by 
trivalent cations with similar size, giving positively charged sheets, which results in an LDH 
structure. LDHs have a general formula [M2+1–x M3+x (OH) 2] x+ (An–) x/n·mH2O, where M 
represents metal cations and A stands for interlayer anions. LDHs have attracted extensively 
clinical attention due to biocompatibility and potential therapeutic biomolecule delivery 
ability.6-8 Till now, due to the colloidal instability of LDHs in the biological environment, most 
reports focus on in vitro cellular delivery, and ligand modification of LDHs for potential in 
vivo work with targeting capability has been progressed slowly.  
Normally, active targeting ligands can be attached onto the nanocarriers surface through 
various conjugation strategies, and many researches have been devoted into this area.9 The 
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traditional modification of LDH nanoparticles with targeting ligands involves serial chemical 
reactions either in organic solvent or electrolytic solution.10,11 In general, for in situ surface 
functionalization of ligands onto nanoparticles, an excess amount of reactants are required for 
sufficient chemical reactions. Moreover, the ligand-modified nanoparticles fail to be precisely 
engineered in a meaningfully repeatable manner and easily varied from batch to batch, 
eventually triggering unpredictable therapeutic effect.10,11 
In some cases, inter-matrix biomaterials were pre-conjugated with ligands and then applied to 
functionalize the nanoparticles with targeting ability. The pre-functionalization of biomaterials 
render desired nanoparticles with reduced fabrication and purification procedures, enabling 
narrowly variation from batch to batch.12 Previously, we developed a strategy to improve the 
colloidal stability of LDHs by coating bovine serum albumin (BSA) onto LDHs surface. As-
formed BSA-LDH complexes were colloidally stable in various electrolyte solutions. Further 
cross-linking of BSA made the complexes to be even colloidally stable and easily dispersed in 
electrolyte solutions after freeze-drying.13 Based on these findings, we proposed a new strategy 
to conjugate angiopep-2 (Ang2) and rabies virus glycoprotein peptide (RVG) ligands to BSA 
and enable LDHs to target U87 glioma cells and Neuron 2a (N2a) cells, respectively in this 
research. It is known that Ang2 and RVG ligands can bind to low density lipoprotein (LRP) 
receptors and nicotinic acetylcholine receptors (nAchR) that are widely expressed in U87 and 
N2a cells respectively. Interestingly, the receptors for Ang2 and RVG also overexpressed in 
the brain endothelial cells which mainly form the blood brain barrier,14,15 and our LDHs is 
expected to target these cells and help pass through blood brain barrier.  
 
Therefore, the objectives of this research were to: (1) control-prepare BSA-coated LDH 
nanoparticles with Ang2/RVG ligand conjugated in a designed number; (2) ascertain that target 
ligands on the LDH surface enhance delivery to U87 and N2a cells; (3) investigate the effect 
of target ligands on the cellular uptake mechanism, and (4) confirm that target ligand enhances 
the cytotoxicity of drug-LDH nanoparticles. The current methods for LDHs surface 
modification may provide a feasible way to apply LDH nanoparticle for target in vivo delivery.  
 
5.2 Experimental section 
 
5.2.1 Materials 
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Complementary strands of dsDNAs were purchased from GeneWorks and annealed at 75°C 
for 10 min. One strand of the duplex was covalently coupled to the Cy3 fluorophore at the 
5′end before annealing. Glutaraldehyde (GTA) solution (25%) was bought from Ajax 
Finechem, and sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-
carboxylate) and other chemicals were from Sigma-Aldrich if not illustrated specifically. Water 
used in experiments was deionized Milli-Q water. Angiopep-2 (Ang2: 
TFFYGGSRGKRNNFKTEEYC) and Rabies virus glycoprotein (RVG: 
YTIWMPENPRPGTPCDIFTNSRGKRASNGC) peptide were purchased from Biomatik. 
Sulfo-SMCC (MW =436 Da) was obtained from Sigma-Aldrich. Amicon ultra-0.5 centrifugal 
filter units were purchased from Millipore Company. All the other solvents were of analytical 
or chromatographic grade.   
  
5.2.2 Synthesis of peptide-modified LDH delivery system  
 
Synthesis of LDH nanoparticles and LDH-5-FU  
Mg2Al-Cl-LDH (pristine LDH) was prepared using a co-precipitation-hydrothermal treatment 
method, as reported previously.16-18 In brief, LDH was synthesised by mixing 40 ml NaOH 
solution (0.15 M) with 10 ml salt solution containing MgCl2 (3.0 mmol) and AlCl3 (1.0 mmol) 
under vigorous stirring. The resultant precipitate was washed and then hydrothermally treated 
at 100 oC for 16 h, giving an LDH suspension with the mass concentration of 4.0 mg/ml. The 
5-FU/Mg2Al-LDH hybrid (5-FU/LDH) was synthesised via ion exchange, prior to 
hydrothermal treatment. In this process, the resultant precipitate was collected and resuspended 
in 40 mL of the basic solution containing 0.3 mmol of 5-FU (neutralized with dilute NaOH 
solution, with pH 8–9) under stirring for 1 h. After washing two times, the suspension was 
transferred to an autoclave (stainless steel with a teflon lining) and incubated at 100°C for 16 
hours. After hydrothermal treatment, a transparent, homogeneous 5-FU/LDH suspension was 
obtained.19,20 The loading amount of 5-FU drug was determined using UV-Vis at 265 nm. 
BSA activation and conjugation with peptides  
10 mg/ml BSA solution in conjugation buffer (phosphate-buffered saline:100 mM sodium 
phosphate, 150 mM sodium chloride, 3 mM EDTA, pH 7.2) was Size/Pdi and added to a 
solution containing 10-fold molar excess of sulfo-SMCC crosslinker over the amount of BSA 
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protein to activate sufficient maleimide groups and conjugate sulfhydryl-containing 
Ang2/RVG peptides with BSA. The reaction of the maleimide groups and the thiol groups 
proceeded rapidly and selectively under mild coupling conditions (pH 6.5-7.5) to yield a stable, 
covalently linked 10 mg/ml of Ang2/RVG-SMCC-BSA conjugate. The resulting complex was 
purified by Millipore ultrafiltration tube with a molecular weight cutoff (MWCO) of 30 KD to 
get rid of the free excess peptide and salts.   
Characterisation of ligand number  
Matrix Assisted Laser Desorption Ionization—Time of Flight (MALDI-TOF) and Ellman’s 
reagent 5, 5’-dithio-bis-(2-nitrobenzoic acid), also known as DTNB, were used for quantitating 
the molecular weight or free sulfhydryl groups in solutions before and after BSA activation 
and peptide conjugation.  MALDI-TOF mass spectra were obtained using a Bruker Autoflex 
III Smartbeam TOF/TOF 200. All spectra were recorded in linear mode. For testing, a matrix 
thin layer on a ground steel target using matrix solution I (Sinapinic Acid saturated in EtOH) 
was prepared. Equal volumes (2 µl each) of sample solution and matrix solution II (Sinapinic 
Acid saturated in TA30) was pre-mixed and 0.5 μl of this mixture was applied on top of the 
matrix thin layer prepared. The number-average molecular weight (MW) and weight-average 
molecular weight (MW) were calculated from the MALDI-TOF spectra using Data Explorer 
software (Applied Biosystems, Framingham, MA). The number of thiol groups before and after 
BSA conjugation with peptides was calculated by the changes of the DTNB concentration. 
DTNB reacts with free thiol groups to yield a mixed disulfide and 2-nitro-5-thiobenzoic acid 
(TNB), where the TNB has a high molar extinction coefficient at 412 nm. During the test, 125 
ul tested sample was mixed with 50 μl of Ellman’s reagent solution and 2.625 ml of reaction 
buffer (0.1M sodium phosphate, pH 8.0, containing 1mM EDTA) and left to react for 15 mins 
at room temperature. As a blank, 125 μl of reaction buffer was added instead of the tested 
sample. The absorbance at 412 nm was then measured.  
Preparation of NPs and Ang2/RVG-NPs with or without 5-FU 
Two millilitres of 4 mg/ml LDH or LDH-5-FU suspension was added into 2 ml 10 mg/ml of 
BSA (or BSA mixed with BSA-Ang2/RVG at a mass ratio of 19:1) stock solution drop by drop 
with vigorously magnetic stirring for 30 mins to ensure saturated adsorption. Then the adsorbed 
BSA was crosslinked by glutaraldehyde overnight as previous reported.13,21 The resulted 
Ang2/RVG-modified and unmodified nanoparticles were named as Ang2/RVG-NPs (5-
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FU/Ang2-NPs or 5-FU/RVG-NPs) and NPs (5-FU/NPs), respectively. Nanoparticles were 
subjected to centrifugation and washed by milli-Q water to remove the excess BSA-SMCC-
Ang2/RVG before conducting cellular uptake.  
Preparation of NPs and Ang2/RVG-NPs loaded with dsDNA-Cy3  
Loading dsDNA-Cy3 onto NPs and Ang2/RVG-NPs was similar to the preparation of 
LDH/dsDNA as reported previously.6,22 Briefly, dsDNA-Cy3 loaded nanoparticles were 
prepared by adding dsDNA-Cy3 to the Ang2/RVG-NPs and NPs at an LDH/dsDNA mass ratio 
of 40:1. The obtained dsDNA-Cy3 loaded NPs and Ang2/RVG-NPs were then cross-linked by 
glutaraldyhyde overnight as previously interpreted.13 The acquired nanoparticles were 
subjected to centrifugation and washed by Milli-Q water to remove the excess BSA-SMCC-
Ang2/RVG before conducting cellular uptake test.   
Characterisation of physicochemical properties 
The hydrodynamic size and the surface charge (zeta potential) of LDH NPs, Ang2-NPs and 
RVG-NPs were characterised with a Nano Zetasizer instrument utilizing dynamic light 
scattering (DLS).  
5.2.3 In-vitro assays  
 
Cell line 
The U87 cell line was obtained from the QIMR Berghofer medical research institute. U87 cells 
were cultured in RPMI medium, supplemented with 10% FBS, 100 U/ml penicillin and 100 
µg/ml streptomycin.  The Neura 2a (N2a) cells were obtained from the Queensland brain 
institute and cultured in DMEM medium, supplemented with 10% FBS, 100 U/ml penicillin 
and 100 µg/ml streptomycin. All cells were cultured in incubators maintained at 37 °C with 5% 
CO2 under fully humidified conditions. All cell experiments were performed in the logarithmic 
phase of growth. 
Cellular uptake assay 
U87 and N2a cells were seeded at a density of 1× 105 cells/well in 12-well plates (Corning 
Coaster) and incubated for 24 h. Then U87 and N2a cells were incubated with dsDNA-Cy3 
labelled Ang2/RVG-NPs and NPs at the dsDNA-Cy3 concentration range of 20-120 µM for 2 
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h at 37 °C. Cells without any treatment were used as control. Time dependent cellular uptake 
was also tested by incubating cells for 0.5, 1 and 2 h at the concentration of 60 µM and 120 
µM of dsDNA-Cy3, respectively. After treatment, the culture medium was removed and the 
cells were washed three times with ice-cold PBS (pH 7.4) and harvested. The cellular uptake 
was measured by flow cytometry analysis using FL-2 log filter for collection of fluorescence 
intensity. Each experiment was carried out in duplicate and 3 independent experiments were 
performed. 
Cellular uptake mechanism of Ang2/RVG-NPs 
U87 and N2a cells were seeded at a density of 1× 105 cells/well in 12-well plates (Corning 
Coaster) and incubated for 24 h. After checking the confluency and morphology, 
chlorpromazine hydrochloride (CPZ, 10 µg/mL), sucrose (0.45 M), nystatin (25 µg/mL), 
Ang2/RVG (200 µg/mL) were added into each well and incubated for 20 mins. Then the culture 
medium was withdrawn from the well, and dsDNA-Cy3 labelled Ang2/RVG-NPs along with 
different compounds in the medium (the concentration of each compound was equal to that 
described above) were added. After 120 mins incubation, the medium was discarded and the 
cells were washed three times with ice-cold PBS. The cellular uptake was measured by flow 
cytometry analysis using FL-2 log filter for collection of fluorescence intensity. Each 
experiment was carried out in duplicate and 3 independent experiments were performed. 
Intracellular tracking of NPs and Ang2/RVG-NPs 
U87 cells and N2a cells were seeded on coverslips that were placed in 6-well plates. After 24 
h, cells were incubated with dsDNA-Cy3-labeled Ang2/RVG-NPs or NPs for 4 h at 37 °C. 
Cells were washed twice with PBS buffer, fixed and moved to the glass slides containing DAPI 
mounting medium. After nucleus staining, the confocal images were taken on Zeiss LSM 710 
confocal microscope equipped with an inverted microscope. For U87 and N2a cells, z stacks 
of typically 0.3 µm, 30-40 slices were imaged, each slice being the average of four laser scans. 
Microscopes Axio Imager Azure was also used to take images.   
In vitro cytotoxicity and anti-proliferative activity against U87 and N2a cells  
U87 and N2a cells were seeded in a 96-well at a density of 3000 cells/well in growth medium 
(RPMI and DMEM medium respectively, containing 10% foetal calf serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin), and incubated at 37 °C in a humidified atmosphere 
with 5% CO2. Cytotoxicity was examined by the MTT (Sigma) assay. Twenty-four hours after 
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seeding, the cells were treated with growth medium containing NPs, Ang2-NPs or RVG-NPs 
(LDH 10, 50, 100, 200 or 500 µg/ml). Growth medium was used as control. For anti-
proliferative activity test, U87 and N2a cells were seeded in 96-well plates at a density of 3000 
cells/well and cultured at 37Ԩ for 24 h. Then cells were incubated with 5-FU/NPs and 5-
FU/Ang2-NPs or 5-FU/RVG-NPs at the 5-FU concentration of 0-20 µg/ml for 72 h, and the 
culture medium was used as control. At the end of incubation, 20 µl of 5 mg/ml MTT solution 
was added into each well. After incubation of 4 h in darkness, MTT solution was removed, and 
200 µl DMSO added in each well to dissolve MTT formazan crystal. Absorbance was measured 
at 490 nm on a SpectraMax M5 microplate reader, and cell viability was calculated as 
(absorbance in the treatment well)/(absorbance in the control well) × 100%. Concentrations of 
5-FU showing 50% reduction in cell viability (i.e. IC50) were calculated. Each experiment was 
carried out in duplicate and 3 independent experiments were performed.    
5.2.4 Hemolysis assay 
 
Fresh ethylenediamine tetraacetic acid (EDTA)-stabilised blood samples were collected from 
C57BL/6 male mice in the AIBN animal facility, University of Queensland Biological 
Resources. Whole blood was diluted in PBS (1 ml blood in 10 ml PBS), and the packed red 
blood cells (RBCs) were isolated via centrifugation at 1600 rpm for 5 mins, and further washed 
for more than five times with sterile isotonic PBS (until no red color could be seen in 
supernatant). Then, 200 µL of packed RBCs were diluted into 4 mL of PBS. The diluted RBCs 
suspension (0.2 mL) was then mixed with BSA-LDHs, NPs, Ang2-NPs or RVG-NPs PBS 
solution (0.8 mL) at various concentrations. PBS and water (0.8 mL) were used instead of LDH 
nanoparticles solution as negative and positive control, respectively. The mixture was gently 
shaken and incubated at room temperature for 2 h, followed by centrifugation at 1600 rpm for 
5 min. The supernatant absorbance at 541 nm (Abs) was measured by a multifunctional 
microplate reader (infinite M200, Tecan). The percentage of RBCs hemolysis was calculated 
using the following formula: 
ܪ݁݉݋݈ݕݏ݅ݏ	ܲ݁ݎܿ݁݊ݐܽ݃݁ ൌ ሺAbs௦௔௠௣௟௘ 	െ Abs௡௘௚௔௧௜௩௘	௖௢௡௧௥௢௟ሻሺAbs௣௢௦௜௧௜௩௘	௖௢௡௧௥௢௟ െ Abs௡௘௚௔௧௜௩௘	௖௢௡௧௥௢௟ሻ 	ൈ 100	% 
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Statistics 
The data are presented as the mean ± SD. One-way or two-way ANOVA with Bonferroni’s 
post-hoc test was used to assess statistical significance. *p< 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001.  
 
5.3 Results and Discussion 
 
Preparation and characterisation of ligand modified LDH nanoparticles  
As shown in Figure 5.1, the first reaction step in our strategy was to conjugate a 
heterobifunctional crosslinker sulfo-SMCC to activate BSA where the amine groups of BSA 
reacted with N-hydroxysuccinimide (NHS) ester to form amide bonds. In the second step, the 
thiol groups of peptides reacted with reactive maleimide groups in activated BSA. Therefore, 
the peptides were conjugated with BSA (BSA-Ang2 or BSA-RVG).23, 24 
 
Figure 5.1 The strategy of constructing peptide-conjugated nanoparticles and MALDI-TOF 
detection of BSA molecular weight after activation and peptide conjugation 
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Table 5.1 MALDI-TOF detection of BSA molecular weight after activation and peptide 
conjugation 
*   Sulfo-SMCC MW: 436; Ang2 MW: 2404.66  RVG 29 MW: 3369.82  
Maldi-tof is a very powerful analytical technique for the analysis of biomolecules (such as 
DNA, proteins, peptides and sugars) and large organic molecules (such as polymers, 
dendrimers and other macromolecules),25-27 by providing accurate molecular weight.28 As 
shown in Figure 5.1 and listed in Table 5.1, the original BSA had a molecular weight of 66593 
D, similar to the reported for BSA.29 After activation by the linker sulfo-SMCC, the synthesised 
complex BSA-SMCC had a molecular weight of 70182 D, which means that approximately 
8.2 sulfo-SMCC were conjugated to each BSA. The yielding peptide-conjugated BSA (BSA-
Ang2 or BSA-RVG) had a molecular weight of 86351 D and 91073 D, respectively, which 
indicate that there were around 6.7 Ang2 and 6.2 RVG peptides conjugated to each BSA. 
Moreover, the Ellman’s method was also used to identify that the peptide ligand was 
successfully conjugated with activated BSA.30 As shown in Table 5.S1, the absorbance value 
at 412 nm tested by Ellman’s method decreased after reaction, which means that the sulfydryl-
groups containing peptide was used to react with maleimide groups in the activated BSA. This 
adjuvant method also indicated that the peptides have conjugated with BSA successfully. 
Following our previous experience, the mixture of BSA-Ang2/RVG and BSA was prepared at 
a molar ratio of 19:1 (BSA: BSA-Ang2/RVG=19:1) and then coated onto the surface of LDHs 
through electrostatic interaction and subsequently crosslinked by GTA (Figure 5.1, step 3 and 
4) to obtain stabilised and ligand modified LDH-BSA complexes, 13,21,31,32 In such a way, Ang2 
   MW Sulfo-SMCC*  
number 
Peptide* 
number  
BSA 
BSA-SMCC             
  66593 
 70182 
     - 
     8.2  
  - 
  - 
BSA-SMCC-Ang2    86351                   8.2                                   6.7    
BSA-SMCC-RVG   91073    8.2  6.2 
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or RVG peptides were conjugated to LDH nano-carrier surface via BSA (Ang2-NPs and RVG-
NPs), respectively for brain cell targeting delivery. 
Table 5.2 Size distribution and zeta potential of the conjugates (mean ± SD, n = 3). 
 Z-Average 
(d.nm)/PDI            
Zeta Potential (mV)            
LDH 103.3/0.179 
 
30.5 
 
BSA-LDH                                
 
170.5/0.198       
 
 -22.9 
 
BSA-LDH-GTA (NPs)            
 
170.4/0.197 
 
 -25.5 
 
BSA-LDH-Ang2-GTA 
 (Ang2-NPs)                     
 
169.9/0.201          
 
 -18.4 
 
BSA-LDH-RVG-GTA 
(RVG-NPs)  
 
170.3/0.185      
 
 -16.0 
 
5-FU/LDH                       
 
90.8/0.185           28.9 
 
5-FU (wt%): the loading capacity of 5-FU/LDH hybrids determined via UV-vis at 265 nm 
was 14.59% . 
Table 5.2 shows the size and surface charge of LDH nano-carriers. The particle size before and 
after BSA coating increased from original 100 nm to around 170 nm while the zeta potential 
decreased from 30.5 mV to approximately -23 mV, which is in consistence with previous 
study.13,21 After GTA crosslinking, the size was kept the same while the zeta potential slightly 
reduced due to the reaction of amino groups for crosslinking. Clearly, the particle size 
distribution was all moderately narrow in three cases, with the polydispersity index (PDI) close 
to 0.20. Attaching Ang2 or RVG peptides to the LDH nano-carriers did not significantly affect 
the size and the size distribution. Meanwhile, the zeta potential slightly changed from -22.9 
mV to -18.4 mV (Ang2 peptides) and -16.0 mV (RVG peptides) after peptides conjugation, 
because the side chains of both peptides carry 2 net positive charges (2 negative charges and 4 
positive charges). Altogether, these evidences suggest that Ang2 or RVG peptides are 
conjugated.33 Such active targeting nanoparticles may accumulate more readily in tumour 
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tissue and facilitate targeted cell uptake due to the enhanced permeability and retention effect. 
34,35 
Compared with LDHs, the average size of 5-FU incorporated LDHs (5-FU/LDH) was 
decreased to 90.8 nm (Table 5.2),  which can be attributed to the inhibition of incorporation 
anionic organic drug 5-FU to the hydroxide layer lateral growth, as previously interpreted.36 
The similarity in zeta potential suggests that 5-FU loading was conducted through ion 
exchange,37 with the loading of around 0.60 mg/ml (5-FU) in 4.0 mg/ml (LDH) suspension.   
 
Here we developed a new and facile method to synthesise colloidally stabilised targeting LDH 
system by pre-conjugating Ang2 or RVG with BSA, followed by coating and crosslinking. The 
pre-conjugation of BSA with desired ligands has successfully offered a simplified and 
amenable procedure with narrowly variation and avoided the complicated post-particle 
modification on LDHs. The conventional modification includes serial chemical reactions in 
organic solvent for targeting ligand conjugation, which leads to concerns of increased toxicity 
and colloidal stability for biological application.10,11 Moreover, the variation of surface 
property would be accompanied with a serious of downstream chain reactions, consequently 
compromising other properties such as antibiofouling property, stability and drug release.38 
Here, the colloidal stability of LDH nanoparticles in electrolytes buffer is always the first 
concern. Previous studies have evidenced that the LDH nanoparticles immediately form 
aggregation once exposure into the electrolytes buffer (physiological environment).17 The 
aggregation has been well prohibited by coating BSA onto the LDH surface.21 In this study, a 
further conjugation of the other modalities such as specific targeting ligands with BSA does 
not only keep the colloidal stability, but also makes the LDHs as a targeting delivery 
nanoplatform.13,21,10  
 
Improved uptake of Ang2/RVG-NPs by U87 and N2a cells 
 
Cy3-labeled nanoparticles were used to quantifying concentration- and time- dependent 
cellular uptake kinetics, the results of which are shown by flow cytometry. In this study, two 
receptor-mediated transport promoting ligands (Ang2 and RVG) were exploited for the 
modification of LDH NPs and target to U87 and N2a cells, respectively. As shown in Figure 
5.2A and 5.2B, Ang2-NPs increased the U87 cell uptake efficiency compared to ligand-
unmodified NPs. In particular, the U87 cell uptake efficiency was significantly higher at the 
dsDNA-Cy3 concentration of 40 and 60 µM with the incubation time of 2 h. Similarly, the N2a 
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cellular uptake of Cy3-labeled RVG-NPs also demonstrated a time- and concentration- 
dependent mode (Figure 5.2C and 5.2D). After 2 h incubation, cellular uptake of Cy3-labeled 
RVG-NPs was significantly higher than Cy3-labeled NPs at the dsDNA-cy3 concentration of 
60 and 120 µM, increasing by 41% and 36%, respectively. To further confirm whether the 
specific uptake was induced by ligand-receptor mediated endocytosis other than the change of 
surface properties, we particularly incubated N2a cells with Ang2-LDHs and U87 cells with 
RVG-LDHs (they were non-target cells), respectively. Figure S5.2 shows that there was no 
specific enhancement induced by the exchange targeting, as N2a and U87 do not have the 
receptors for Ang2 and RVG, respectively. These results were in agreement with reports that 
target ligands (Ang2 and RVG) facilitated nanoparticles uptake by the target cells other than 
non-target cells.39  
 
     
 
     Figure 5.2 Cellular uptake of Ang2/RVG-NPs/NPs. (A) and (C) Cellular uptake of Ang2-
NPs/NPs  by U87 cells and RVG-NPs/NPs by N2a cells at the dsDNA-Cy3 concentration range 
of 20-120 µM for 2 h. (B) and (D) Cellular uptake of Ang2-NPs/NPs (60 µM dsDNA-Cy3) by 
U87 cells and RVG-NPs/NPs (120 µM dsDNA-Cy3) by N2a cells for different periods of 
incubation times.  
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Active targeting mediated by affinity ligands provides an alternative delivery for cancer 
treatment. Nanoparticles functionalised with targeting ligands preferentially increase the drug 
delivery to the target cells expressing cognate counterparts.40 In a similar study about Ang2-
conjugated poly(ethylene glycol)-co-poly(e-caprolactone) nanoparticles (Ang2-PEG-PCLs) 
drug delivery system for U87 cells, the cellular uptake of 500 mg/ml rhodamine isothiocyanate 
(RBITC)-labelled Ang2-PEG-PCLs exhibited a time-dependent mode and significantly higher 
than RBITC-labelled PEG-PCLs when the incubation time ranging from 30 to 120 mins.41 As 
proposed, surface modification with Ang2 or RVG endows LDH NPs with enhanced cellular 
uptake efficiency, in good agreement with previous studies. Such uptake profile may provide 
view for optimizing the therapeutic intervention.15, 42, 43 
 
Intracellular localisation of NPs and Ang2/RVG-NPs and uptake mechanism  
 
The intracellular localisation of Cy3-labelled Ang2/RVG-NPs and NPs in U87 and N2a cells 
was evaluated by confocal microscopy (Figure 5.3A and 5.3B) and fluorescence microscope 
(Figure S5.3A-S5.3B). Both confocal images and fluorescence images show that U87/N2a cells 
treated with Cy3-labelled Ang2/RVG-NPs exhibited higher fluorescent intensity in comparison 
with Cy3-labeled NPs. Particularly, the intracellular location examination by confocal ortho-
images of z-stacks illustrates that the nanoparticles were mainly present in cytoplasm. The 
images indicate that Ang2/RVG peptide modified LDHs could facilitate the internalisation 
process, leading to enhanced nanoparticles accumulation throughout the cytoplasm of U87 and 
N2a cells, while the localisation seems to be very similar in both cases for target and non-target 
LDH nanoparticles, which is in consistence with our previous report.44 
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Figure 5.3 Intracellular localisation of Ang2-NPs/NPs incubated with U87 cells for 4 h (A)  
and RVG-NPs/NPs incubated with N2a cells for 4 h (B). The nuclei were stained with DAPI. 
The centre merged confocal ortho-images of z-stacks were X-Y view, the images above and 
right were X-Z and Y-Z views (cross section at the red and green line). 
 
 
B 
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Figure 5.4 Cellular uptake of NPs and Ang2/RVG-NPs by U87 cells (A) and N2a cells (B) in 
presence of specific inhibitors. Cells were pretreated with various inhibitors for 20 mins, 
followed by treating with Ang2/RVG-NPs for 2 h. 
 
In order to elucidate the internalisation mechanism of Ang2/RVG-NPs, the effects of 
endocytosis inhibitors on cellular uptake kinetics were evaluated quantitatively. Inhibitors for 
clathrin-mediated (CPZ and surcose) or caveolin-mediated (NYS) endocytosis were selected. 
As shown in Figure 5.4A, both CPZ and sucrose were found to inhibit the U87 cellular uptake 
of Ang2 -NPs, decreasing by 63% and 37.6%, respectively. Incubation of U87 cells with 
nystatin also significantly reduced the cellular uptake of Ang2-NPs. These results suggest that 
clathrin-mediated endocytosis and caveolae-mediated endocytosis are the main contributor to 
internalisation of Ang2-NPs by U87 cells.  
 
Similarly, Figure 5.4B shows that incubation of N2a cells with CPZ and sucrose effectively 
reduced the cellular uptake of RVG-NPs to 50.8% and 83.2%, respectively, indicating the 
involvement of clathrin-mediated endocytosis in the cellular uptake of RVG-NPs. However, 
nystatin was not found to significantly affect the cellular uptake of RVG-NPs by N2a cells. 
Thus, clathrin-mediated endocytosis may contribute to major internalization of RVG-NPs by 
N2a cells.  
 
